The biological and clinical impact of deletions before and after large chromosomal gains in multiple myeloma
Cirrincione A, Poos A, Ziccheddu B, Kaddoura M, Baertsch M, Maclachlan K, Chojnacka M, Diamond B, John L, Reichert P, Huhn S, Blaney P, Gagler D, Rippe K, Zhang Y, Dogan A, Lesokhin A, Davies F, Goldschmidt H, Fenk R, Weisel K, Mai E, Korde N, Morgan G, Usmani S, Landgren O, Raab M, Weinhold N, Maura F
BLOOD. 2024;144(7):771-783.

BCMA x CD3 T-cell engager in a patient with penta-refractory multiple myeloma and HIV: a clinical and immunological report
Cords L, Schaefers C, Kamili A, Hoffmann C, Cichutek S, Haag F, Polywka S, Bokemeyer C, Leypoldt L, Alsdorf W, Schulze zur Wiesch J, Weisel K
HAEMATOLOGICA. 2024;109(9):3071-3077.

Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma
Einsele H, Moreau P, Bahlis N, Bhutani M, Vincent L, Karlin L, Perrot A, Goldschmidt H, van de Donk N, Ocio E, Martinez-Lopez J, Rodríguez-Otero P, Dytfeld D, Diels J, Strulev V, Haddad I, Renaud T, Ammann E, Cabrieto J, Perualila N, Gan R, Zhang Y, Parekh T, Albrecht C, Weisel K, Mateos M
ADV THER. 2024;41(4):1576-1593.

Multiple myeloma refractory to lenalidomide: A systematic literature review of trials and real-world evidence
Hartley-Brown M, Weisel K, Bitetti J, Carter J, McNamara S, Purser M, Palumbo A, Richardson P
BRIT J HAEMATOL. 2024;205(3):780-797.

Multiple myeloma in the young: insights on prognosis, clinical features and treatment outcome derived from nationwide German registry data and a nested multicenter sample
Kamili A, Ahmadi P, Leypoldt L, Marquard F, Schaefers C, Kosch R, Peters F, Kusche H, Zamrik T, Hanoun C, Seib M, Shumilov E, Leitner T, Khandanpour C, Bokemeyer C, Weisel K, Ghandili S
HAEMATOLOGICA. 2024;109(11):3795-3799.

CD8+ CD28- regulatory T cells after induction therapy predict progression-free survival in myeloma patients: results from the GMMG-HD6 multicenter phase III study
Kriegsmann K, Ton G, Awwad M, Benner A, Bertsch U, Besemer B, Hänel M, Fenk R, Munder M, Dürig J, Blau I, Huhn S, Hose D, Jauch A, Mann C, Weinhold N, Scheid C, Schroers R, von Metzler I, Schieferdecker A, Thomalla J, Reimer P, Mahlberg R, Graeven U, Kremers S, Martens U, Kunz C, Hensel M, Seidel-Glätzer A, Weisel K, Salwender H, Müller-Tidow C, Raab M, Goldschmidt H, Mai E, Hundemer M
LEUKEMIA. 2024;38(7):1621-1625.

Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma
Leypoldt L, Tichy D, Besemer B, Hänel M, Raab M, Mann C, Munder M, Reinhardt H, Nogai A, Görner M, Ko Y, de Wit M, Salwender H, Scheid C, Graeven U, Peceny R, Staib P, Dieing A, Einsele H, Jauch A, Hundemer M, Zago M, Požek E, Benner A, Bokemeyer C, Goldschmidt H, Weisel K
J CLIN ONCOL. 2024;42(1):26-37.

Plain language summary of isatuximab plus carfilzomib, lenalidomide, and dexamethasone for the treatment of people with high-risk newly diagnosed multiple myeloma
Leypoldt L, Tichy D, Besemer B, Hänel M, Raab M, Mann C, Munder M, Reinhardt H, Nogai A, Görner M, Ko Y, de Wit M, Salwender H, Scheid C, Graeven U, Peceny R, Staib P, Dieing A, Einsele H, Jauch A, Hundemer M, Zago M, Požek E, Benner A, Bokemeyer C, Goldschmidt H, Weisel K
FUTURE ONCOL. 2024;1-15.

Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee
Lin Y, Qiu L, Usmani S, Joo C, Costa L, Derman B, Du J, Einsele H, Fernandez de Larrea C, Hajek R, Ho P, Kastritis E, Martinez-Lopez J, Mateos M, Mikhael J, Moreau P, Nagarajan C, Nooka A, O'Dwyer M, Schjesvold F, Sidana S, van de Donk N, Weisel K, Zweegman S, Raje N, Otero P, Anderson L, Kumar S, Martin T
LANCET ONCOL. 2024;25(8):e374-e387.

Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial
Mai E, Goldschmid H, Miah K, Bertsch U, Besemer B, Hänel M, Krzykalla J, Fenk R, Schlenzka J, Munder M, Dürig J, Blau I, Huhn S, Hose D, Jauch A, Kunz C, Mann C, Weinhold N, Scheid C, Schroers R, von Metzler I, Schieferdecker A, Thomalla J, Reimer P, Mahlberg R, Graeven U, Kremers S, Martens U, Kunz C, Hensel M, Benner A, Seidel-Glätzer A, Weisel K, Raab M, Salwender H
LANCET HAEMATOL. 2024;11(2):e101-e113.

Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: results from the EPICOVIDEHA survey
Mai E, Hielscher T, Bertsch U, Salwender H, Zweegman S, Raab M, Munder M, Pantani L, Mancuso K, Brossart P, Beksac M, Blau I, Dürig J, Besemer B, Fenk R, Reimer P, van der Holt B, Hänel M, von Metzler I, Graeven U, Müller-Tidow C, Boccadoro M, Scheid C, Dimopoulos M, Hillengass J, Weisel K, Cavo M, Sonneveld P, Goldschmidt H
LEUKEMIA. 2024;38(3):640-647.

LocoMMotion: a study of real-life current standards of care in triple-class exposed patients with relapsed/refractory multiple myeloma - 2-year follow-up (final analysis)
Mateos M, Weisel K, De Stefano V, Goldschmidt H, Delforge M, Mohty M, Dytfeld D, Angelucci E, Vincent L, Perrot A, Benjamin R, van de Donk N, Ocio E, Roccia T, Schecter J, Koskinen S, Haddad I, Strulev V, Mitchell L, Buyze J, Filho O, Einsele H, Moreau P
LEUKEMIA. 2024 [Epub ahead of print].

Characterization and Outcomes of Spanish Patients With Relapsed/Refractory Multiple Myeloma Included in the LocoMMotion Study
Mateos M, Weisel K, Diels J, Arribas A, Tamayo M, Schecter J, Roccia T, Haddad I, Pacaud L, Moreau P
CL LYMPH MYELOM LEUK. 2024;24(4):224-231.e2.

Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma
Mateos M, Weisel K, Terpos E, Delimpasi S, Kastritis E, Zamagni E, Delforge M, Ocio E, Katodritou E, Gay F, Larocca A, Leleu X, Otero P, Schjesvold F, Cavo M, Dimopoulos M
HAEMATOLOGICA. 2024;109(7):2337-2340.

Temporal Genomic Dynamics Shape Clinical Trajectory in Multiple Myeloma
Maura F, Kaddoura M, Poos A, Baughn L, Ziccheddu B, Bärtsch M, Cirrincione A, Maclachlan K, Chojnacka M, Diamond B, Papadimitriou M, Blaney P, John L, Reichert P, Huhn S, Gagler D, Zhang Y, Dogan A, Lesokhin A, Davies F, Goldschmidt H, Fenk R, Weisel K, Mai E, Korde N, Morgan G, Rajkumar S, Kumar S, Usmani S, Landgren O, Raab M, Weinhold N
bioRxiv. 2024 [Epub ahead of print].

Genomic Classification and Individualized Prognosis in Multiple Myeloma
Maura F, Rajanna A, Ziccheddu B, Poos A, Derkach A, Maclachlan K, Durante M, Diamond B, Papadimitriou M, Davies F, Boyle E, Walker B, Hultcrantz M, Silva A, Hampton O, Teer J, Siegel E, Bolli N, Jackson G, Kaiser M, Pawlyn C, Cook G, Kazandjian D, Stein C, Chesi M, Bergsagel L, Mai E, Goldschmidt H, Weisel K, Fenk R, Raab M, Van Rhee F, Usmani S, Shain K, Weinhold N, Morgan G, Landgren O
J CLIN ONCOL. 2024;42(11):1229-1240.

Comparative Effectiveness of Teclistamab Versus Real-World Physician's Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma
Moreau P, Mateos M, Gonzalez Garcia M, Einsele H, De Stefano V, Karlin L, Lindsey-Hill J, Besemer B, Vincent L, Kirkpatrick S, Delforge M, Perrot A, van de Donk N, Pawlyn C, Manier S, Leleu X, Martinez-Lopez J, Ghilotti F, Diels J, Morano R, Albrecht C, Strulev V, Haddad I, Pei L, Kobos R, Smit J, Slavcev M, Marshall A, Weisel K
ADV THER. 2024;41(2):696-715.

Prognostic importance of splicing-triggered aberrations of protein complex interfaces in cancer
Newaz K, Schaefers C, Weisel K, Baumbach J, Frishman D
NAR GENOM BIOINFORM. 2024;6(3):lqae133.

Pomalidomide, Bortezomib, and Dexamethasone in Lenalidomide-Pretreated Multiple Myeloma: A Subanalysis of OPTIMISMM by Frailty and Bortezomib Dose Adjustment
Oriol A, Dimopoulos M, Schjesvold F, Beksac M, Facon T, Dhanasiri S, Guo S, Mu Y, Hong K, Gentili C, Galli M, Yagci M, Larocca A, Richardson P, Weisel K
CL LYMPH MYELOM LEUK. 2024;24(3):165-176.e4.

Progression-free survival as a surrogate endpoint in myeloma clinical trials: an evolving paradigm
Pawlyn C, Schjesvold F, Cairns D, Wei L, Davies F, Nadeem O, Abdulhaq H, Mateos M, Laubach J, Weisel K, Ludwig H, Rajkumar S, Sonneveld P, Jackson G, Morgan G, Richardson P
BLOOD CANCER J. 2024;14(1):134.

Navigating High-Risk and Ultrahigh-Risk Multiple Myeloma: Challenges and Emerging Strategies
Rees M, D'Agostino M, Leypoldt L, Kumar S, Weisel K, Gay F
American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 2024;44(3):e433520.

International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma
Rodriguez-Otero P, Usmani S, Cohen A, van de Donk N, Leleu X, Pérez-Larraya J, Manier S, Nooka A, Mateos M, Einsele H, Minnema M, Cavo M, Derman B, Puig N, Gay F, Ho P, Chng W, Kastritis E, Gahrton G, Weisel K, Nagarajan C, Schjesvold F, Mikhael J, Costa L, Raje N, Zamagni E, Hájek R, Weinhold N, Yong K, Ye J, Sidhana S, Merlini G, Martin T, Lin Y, Chari A, Popat R, Kaufman J
LANCET ONCOL. 2024;25(5):e205-e216.

Hämophagozytische Lymphohistiozytose und Makrophagenaktivierungssyndrom: Eine multidisziplinäre Herausforderung
Ruffer N, Kosch R, Weisel K, Kötter I, Krusche M
Z RHEUMATOL. 2024;83(5):376-386.

Cytomegalovirus immunoglobulin serology prevalence in patients with newly diagnosed multiple myeloma treated within the GMMG-MM5 phase III trial
Salwender H, Weinhold N, Benner A, Miah K, Merz M, Haenel M, Jehn C, Mai E, Menis E, Blau I, Scheid C, Hose D, Seckinger A, Luntz S, Besemer B, Munder M, Brossart P, Glass B, Lindemann H, Weisel K, Hanoun C, Schnitzler P, Klemm S, Goldschmidt H, Raab M, Elmaagacli A
HEMATOLOGY. 2024;29(1):2320006.

Diagnosing intravascular B-cell lymphoma using nanopore sequencing of cell-free DNA from cerebrospinal fluid
Schmidt B, Afflerbach A, Ludewig P, Dirksen P, Paulsen F, Magnus T, Alawi M, Schüller U, Weisel K, Bokemeyer C, Christopeit M
ESMO OPEN. 2024;9(11):103974.

Molecular Long-Term Analysis of the GMMG-HD4 Trial in Multiple Myeloma-Patterns of Association of Chromosomal Aberrations with Response and Proliferation Determining Survival in Selecting Treatments in View of Limited Resources in Low- and Middle-Income Countries
Seckinger A, Salwender H, Martin H, Scheid C, Hielscher T, Bertsch U, Hummel M, Jauch A, Knauf W, Emde-Rajaratnam M, Beck S, Neben K, Dührig J, Lindemann W, Schmidt-Wolf I, Hänel M, Blau I, Weisel K, Weinhold N, Raab M, Goldschmidt H, Choon-Quinones M, Hose D
INT J MOL SCI. 2024;25(12):.

Daratumumab for patients with myeloma with early or late relapse after initial therapy: Subgroup Analysis of CASTOR and POLLUX
Spencer A, Moreau P, Mateos M, Goldschmidt H, Suzuki K, Levin M, Sonneveld P, Orlowski R, Yoon S, Usmani S, Weisel K, Reece D, Ahmadi T, Pei H, Garvin Mayo W, Gai X, Carey J, Bartlett J, Carson R, Dimopoulos M
BLOOD ADV. 2024;8(2):388-398.

Safety and efficacy of belantamab mafodotin with pembrolizumab in patients with relapsed or refractory multiple myeloma
Suvannasankha A, Bahlis N, Trudel S, Weisel K, Koenecke C, Oriol A, Voorhees P, Alonso A, Callander N, Mateos M, Reddy N, Hakim S, LaMacchia J, Patel N, Williams D, Jewell R, Zhou X, Gupta I, Opalinska J, Nooka A
CANCER-AM CANCER SOC. 2024;130(15):2629-2641.

Carfilzomib, daratumumab, and dexamethasone (KdD) vs. lenalidomide-sparing pomalidomide-containing triplet regimens for relapsed/refractory multiple myeloman: indirect treatment comparisona
Weisel K, Dimopoulos M, Beksac M, Leleu X, Richter J, Heeg B, Patel S, Majer I, McFadden I, Mikhael J
LEUKEMIA LYMPHOMA. 2024;65(4):481-492.

Outcome of Second Primary Malignancies Developing in Multiple Myeloma Patients
Avivi I, Vesole D, Davila-Valls J, Usnarska-Zubkiewicz L, Olszewska-Szopa M, Milunovic V, Baumert B, Osękowska B, Kopińska A, Gentile M, Puertas-Martinez B, Robak P, Crusoe E, Rodriguez-Lobato L, Gajewska M, Varga G, Delforge M, Cohen Y, Gozzetti A, Pena C, Shustik C, Mikala G, Zalac K, Alexander H, Barth P, Weisel K, Martínez-López J, Waszczuk-Gajda A, Krzystański M, Jurczyszyn A
CANCERS. 2023;15(17):.

A Meta-Analysis of the Efficacy of Pomalidomide-Based Regimens for the Treatment of Relapsed/Refractory Multiple Myeloma After Lenalidomide Exposure
Davies F, Leleu X, Vogel P, Dhanasiri S, Le Nouveau P, Weisel K
CL LYMPH MYELOM LEUK. 2023;23(11):829-837.e1.

Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study
Dimopoulos M, Hungria V, Radinoff A, Delimpasi S, Mikala G, Masszi T, Li J, Capra M, Maiolino A, Pappa V, Chraniuk D, Osipov I, Leleu X, Low M, Matsumoto M, Sule N, Li M, McKeown A, He W, Bright S, Currie B, Perera S, Boyle J, Roy-Ghanta S, Opalinska J, Weisel K
LANCET HAEMATOL. 2023;10(10):e801-e812.

Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group
Dimopoulos M, Merlini G, Bridoux F, Leung N, Mikhael J, Harrison S, Kastritis E, Garderet L, Gozzetti A, van de Donk N, Weisel K, Badros A, Beksac M, Hillengass J, Mohty M, Ho P, Ntanasis-Stathopoulos I, Mateos M, Richardson P, Blade J, Moreau P, San-Miguel J, Munshi N, Rajkumar S, Durie B, Ludwig H, Terpos E
LANCET ONCOL. 2023;24(7):e293-e311.

RNA-sequencing based first choice of treatment and determination of risk in multiple myeloma
Emde-Rajaratnam M, Beck S, Benes V, Salwender H, Bertsch U, Scheid C, Hänel M, Weisel K, Hielscher T, Raab M, Goldschmidt H, Jauch A, Maes K, De Bruyne E, Menu E, De Veirman K, Moreaux J, Vanderkerken K, Seckinger A, Hose D
FRONT IMMUNOL. 2023;14:1286700.

Plain language summary of the MAIA study of daratumumab plus lenalidomide and dexamethasone for the treatment of people with newly diagnosed multiple myeloma
Facon T, Kumar S, Plesner T, Orlowski R, Moreau P, Bahlis N, Basu S, Nahi H, Hulin C, Quach H, Goldschmidt H, Perrot A, Weisel K, Raje N, Macro M, Frenzel L, Leleu X, Wang J, Rampelbergh R, Uhlar C, Vermeulen J, Duran J, Borgsten F, Usmani S
FUTURE ONCOL. 2023;19(13):887-895.

VTd-PACE and VTd-PACE-like regimens are effective salvage therapies in difficult-to-treat relapsed/refractory multiple myeloma: a single-center experience
Ghandili S, Alihodzic D, Wiessner C, Bokemeyer C, Weisel K, Leypoldt L
ANN HEMATOL. 2023;102(1):117-124.

A phase 2 clinical trial of combined BRAF/MEK inhibition for BRAFV600E-mutated multiple myeloma
Giesen N, Chatterjee M, Scheid C, Poos A, Besemer B, Miah K, Benner A, Becker N, Moehler T, Metzler I, Khandanpour C, Seidel-Glaetzer A, Trautmann-Grill K, Kortüm K, Müller-Tidow C, Mechtersheimer G, Goeppert B, Stenzinger A, Weinhold N, Goldschmidt H, Weisel K, Raab M
BLOOD. 2023;141(14):1685-1690.

What do hematologists and oncologists consider necessary for their career?: Results of an online survey in Germany, Austria and Switzerland
Giesler M, Busson-Spielberger M, Miemietz B, de Wit M, Weisel K, Lüftner D
J CANCER RES CLIN. 2023;149(8):5331-5344.

Guidelines for the Use and Reporting of Patient-Reported Outcomes in Multiple Myeloma Clinical Trials
Laane E, Salek S, Oliva E, Bennink C, Clavreul S, Richardson P, Scheid C, Weisel K, Ionova T
CANCERS. 2023;15(24):.

Treatment Patterns, Survival, Quality of Life, and Healthcare Resource Use Among Patients With Triple-Class Refractory Multiple Myeloma in US Clinical Practice: Findings From the Connect MM Disease Registry
Lee H, Ramasamy K, Weisel K, Abonour R, Hardin J, Rifkin R, Ailawadhi S, Terebelo H, Durie B, Tang D, Joshi P, Liu L, Jou Y, Che M, Hernandez G, Narang M, Toomey K, Gasparetto C, Wagner L, Jagannath S
CL LYMPH MYELOM LEUK. 2023;23(2):112-122.

Daratumumab, Bortezomib, and Dexamethasone for Treatment of Patients with Relapsed or Refractory Multiple Myeloma and Severe Renal Impairment: Results from the Phase 2 GMMG-DANTE Trial
Leypoldt L, Gavriatopoulou M, Besemer B, Salwender H, Raab M, Nogai A, Khandanpour C, Runde V, Jauch A, Zago M, Martus P, Goldschmidt H, Bokemeyer C, Dimopoulos M, Weisel K
CANCERS. 2023;15(18):.

Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network
Ludwig H, Terpos E, van de Donk N, Mateos M, Moreau P, Dimopoulos M, Delforge M, Rodriguez-Otero P, San-Miguel J, Yong K, Gay F, Einsele H, Mina R, Caers J, Driessen C, Musto P, Zweegman S, Engelhardt M, Cook G, Weisel K, Broijl A, Beksac M, Bila J, Schjesvold F, Cavo M, Hajek R, Touzeau C, Boccadoro M, Sonneveld P
LANCET ONCOL. 2023;24(6):e255-e269.

Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myeloma
Mai E, Huhn S, Miah K, Poos A, Scheid C, Weisel K, Bertsch U, Munder M, Berlanga O, Hose D, Seckinger A, Jauch A, Blau I, Hänel M, Salwender H, Benner A, Raab M, Goldschmidt H, Weinhold N
BLOOD CANCER J. 2023;13(1):1.

Predictors of Lenalidomide Refractory Relapse Timing With Newly Diagnosed Multiple Myeloma: A FIRST Trial Subanalysis
Manier S, Dimopoulos M, Hulin C, Leleu X, Delforge M, Weisel K, Mouro J, Costa B, Sturniolo M, Facon T
CL LYMPH MYELOM LEUK. 2023;23(9):e297-e306.e1.

Comparative Efficacy of Teclistamab Versus Physician's Choice of Therapy in the Long-term Follow-up of APOLLO, POLLUX, CASTOR, and EQUULEUS Clinical Trials in Patients With Triple-class Exposed Relapsed or Refractory Multiple Myeloma
Mateos M, Chari A, Usmani S, Goldschmidt H, Weisel K, Qi K, Londhe A, Nair S, Lin X, Pei L, Ammann E, Kobos R, Smit J, Parekh T, Marshall A, Slavcev M, Moreau P
CL LYMPH MYELOM LEUK. 2023;23(5):385-393.

Adjusted comparison of outcomes between patients from CARTITUDE-1 versus multiple myeloma patients with prior exposure to proteasome inhibitors, immunomodulatory drugs and anti-CD38 antibody from the prospective, multinational LocoMMotion study of real-world clinical practice
Mateos M, Weisel K, Martin T, Berdeja J, Jakubowiak A, Stewart A, Jagannath S, Lin Y, Diels J, Ghilotti F, Thilakarathne P, Perualila N, Cabrieto J, Haefliger B, Erler-Yates N, Hague C, Jackson C, Schecter J, Strulev V, Nesheiwat T, Pacaud L, Einsele H, Moreau P
HAEMATOLOGICA. 2023;108(8):2192-2204.

Comparative Efficacy of Teclistamab Versus Current Treatments in Real-World Clinical Practice in the Prospective LocoMMotion Study in Patients with Triple-Class-Exposed Relapsed and/or Refractory Multiple Myeloma
Moreau P, van de Donk N, Delforge M, Einsele H, De Stefano V, Perrot A, Besemer B, Pawlyn C, Karlin L, Manier S, Leleu X, Weisel K, Ghilotti F, Diels J, Elsada A, Morano R, Strulev V, Pei L, Kobos R, Smit J, Slavcev M, Mateos M
ADV THER. 2023;40(5):2412-2425.

Measurable Residual Disease Testing in Multiple Myeloma Routine Clinical Practice: A Modified Delphi Study
Ramasamy K, Avet-Loiseau H, Hveding Blimark C, Delforge M, Gay F, Manier S, Martinez-Lopez J, Mateos M, Mohty M, van de Donk N, Weisel K
HEMASPHERE. 2023;7(9):e942.

An indirect treatment comparison of efficacy and health-related quality of life following treatment with idecabtagene vicleucel versus belantamab mafodotin in triple-class exposed relapsed/refractory patients with multiple myeloma
Rodríguez Otero P, Towle K, Cope S, Caisip C, Davies F, Delforge M, Weisel K, Marshall T, Karampampa K, Ayers D, Mojebi A, Braverman J, Farrell J, Dhanda D
LEUKEMIA LYMPHOMA. 2023;64(11):1864-1869.

Increased incidence of immune thrombocytopenia (ITP) in 2021 correlating with the ongoing vaccination campaign against COVID-19 in a tertiary center - A monocentric analysis
Schaefers C, Paulsen F, Frenzel C, Weisel K, Bokemeyer C, Seidel C
BRIT J HAEMATOL. 2023;201(2):222-226.

Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial
Sonneveld P, Chanan-Khan A, Weisel K, Nooka A, Masszi T, Beksac M, Spicka I, Hungria V, Munder M, Mateos M, Mark T, Levin M, Ahmadi T, Qin X, Garvin Mayo W, Gai X, Carey J, Carson R, Spencer A
J CLIN ONCOL. 2023;41(8):1600-1609.

Rates of Influenza and Pneumococcal Vaccination and Correlation With Survival in Multiple Myeloma Patients
Thompson M, Boccadoro M, Leleu X, Vela-Ojeda J, van Rhee F, Weisel K, Rifkin R, Usmani S, Hájek R, Cook G, Abonour R, Armour M, Morgan K, Yeh S, Costello C, Berdeja J, Davies F, Zonder J, Lee H, Omel J, Spencer A, Terpos E, Hungria V, Puig N, Fu C, Ferrari R, Ren K, Stull D, Chari A
CL LYMPH MYELOM LEUK. 2023;23(3):e171-e181.

Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study
Usmani S, Quach H, Mateos M, Landgren O, Leleu X, Siegel D, Weisel K, Shu X, Li C, Dimopoulos M
BLOOD ADV. 2023;7(14):3739-3748.

Impact of Elotuzumab Plus Pomalidomide/Dexamethasone on Health-related Quality of Life for Patients With Relapsed/Refractory Multiple Myeloma: Final Data From the Phase 2 ELOQUENT-3 Trial
Weisel K, Dimopoulos M, San-Miguel J, Paner A, Engelhardt M, Taylor F, Lord-Bessen J, Yip C, Greenwood M, Tang J, Cavo M
HEMASPHERE. 2023;7(3):e843.

Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, MAIA
Cavo M, San-Miguel J, Usmani S, Weisel K, Dimopoulos M, Avet-Loiseau H, Paiva B, Bahlis N, Plesner T, Hungria V, Moreau P, Mateos M, Perrot A, Iida S, Facon T, Kumar S, van de Donk N, Sonneveld P, Spencer A, Krevvata M, Heuck C, Wang J, Ukropec J, Kobos R, Sun S, Qi M, Munshi N
BLOOD. 2022;139(6):835-844.

Meta-analysis of ciltacabtagene autoleucel versus physician's choice therapy for the treatment of patients with relapsed or refractory multiple myeloma
Costa L, Hari P, Berdeja J, De Stefano V, Gay F, Hooper B, Bartlett M, Haltner A, Rosta E, Kumar S, Martin T, Mateos M, Moreau P, Usmani S, Olyslager Y, Schecter J, Roccia T, Garrett A, Lee S, Nesheiwat T, Pacaud L, Zhou C, Samjoo I, Lin Y, Diels J, Valluri S, Weisel K
CURR MED RES OPIN. 2022;38(10):1759-1767.

Perspectives on the Risk-Stratified Treatment of Multiple Myeloma
Davies F, Pawlyn C, Usmani S, San-Miguel J, Einsele H, Boyle E, Corre J, Auclair D, Cho H, Lonial S, Sonneveld P, Stewart A, Bergsagel P, Kaiser M, Weisel K, Keats J, Mikhael J, Morgan K, Ghobrial I, Orlowski R, Landgren C, Gay F, Caers J, Chng W, Chari A, Walker B, Kumar S, Costa L, Anderson K, Morgan G
BLOOD CANCER DISCOV. 2022;3(4):273-284.

Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial
Dimopoulos M, Richardson P, Bahlis N, Grosicki S, Cavo M, Beksaç M, Legieć W, Liberati A, Goldschmidt H, Belch A, Magen H, Larocca A, Laubach J, Petrucci M, Reece D, White D, Mateos M, Špička I, Lazaroiu M, Berdeja J, Kaufman J, Jou Y, Ganetsky A, Popa McKiver M, Lonial S, Weisel K
LANCET HAEMATOL. 2022;9(6):e403-e414.

A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma
D'Souza A, Shah N, Rodriguez C, Voorhees P, Weisel K, Bueno O, Pothacamury R, Freise K, Yue S, Ross J, Polepally A, Talati C, Lee S, Jin Z, Buelow B, Vij R, Kumar S
J CLIN ONCOL. 2022;40(31):3576-3586.

Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA
Facon T, Cook G, Usmani S, Hulin C, Kumar S, Plesner T, Touzeau C, Bahlis N, Basu S, Nahi H, Goldschmidt H, Quach H, Mohty M, Venner C, Weisel K, Raje N, Hebraud B, Belhadj-Merzoug K, Benboubker L, Decaux O, Manier S, Caillot D, Ukropec J, Pei H, Van Rampelbergh R, Uhlar C, Kobos R, Zweegman S
LEUKEMIA. 2022;36(4):1066-1077.

Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial
Goldschmidt H, Mai E, Bertsch U, Fenk R, Nievergall E, Tichy D, Besemer B, Dürig J, Schroers R, von Metzler I, Hänel M, Mann C, Asemissen A, Heilmeier B, Weinhold N, Huhn S, Kriegsmann K, Luntz S, Holderried T, Trautmann-Grill K, Gezer D, Klaiber-Hakimi M, Müller M, Khandanpour C, Knauf W, Scheid C, Munder M, Geer T, Riesenberg H, Thomalla J, Hoffmann M, Raab M, Salwender H, Weisel K
LANCET HAEMATOL. 2022;9(11):e810-e821.

Half-Life Extended Nanobody-Based CD38-Specific Bispecific Killercell Engagers Induce Killing of Multiple Myeloma Cells
Hambach J, Fumey W, Stähler T, Gebhardt A, Adam G, Weisel K, Koch-Nolte F, Bannas P
FRONT IMMUNOL. 2022;13:.

MM-183 CARTITUDE-2 Cohort A: Updated Clinical Data and Biological Correlative Analyses of Ciltacabtagene Autoleucel (cilta-cel) in Lenalidomide-Refractory Patients With Progressive Multiple Myeloma (MM) After 1-3 Prior Lines of Therapy (LOT)
Hillengass J, Cohen A, Delforge M, Einsele H, Goldschmidt H, Weisel K, Raab M, Scheid C, Schecter J, de Braganca K, Varsos H, Yeh T, Mistry P, Roccia T, Corsale C, Akram M, Pacaud L, Nesheiwat T, Agha M, Cohen Y
CL LYMPH MYELOM LEUK. 2022;22(Suppl 2):.

Identification of New Antibodies Targeting Malignant Plasma Cells for Immunotherapy by Next-Generation Sequencing-Assisted Phage Display
Krohn S, Boje A, Gehlert C, Lutz S, Darzentas N, Knecht H, Herrmann D, Brüggemann M, Scheidig A, Weisel K, Gramatzki M, Peipp M, Klausz K
FRONT IMMUNOL. 2022;13:.

Subgroup analysis based on cytogenetic risk in patients with relapsed or refractory multiple myeloma in the CANDOR study
Landgren O, Weisel K, Rosinol L, Touzeau C, Turgut M, Hajek R, Mollee P, Kim J, Shu N, Hu X, Li C, Usmani S
BRIT J HAEMATOL. 2022;198(6):988-993.

Anti-CD38 antibody therapy for patients with relapsed/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomes
Leleu X, Martin T, Weisel K, Schjesvold F, Iida S, Malavasi F, Manier S, Chang-Ki Min , Ocio E, Pawlyn C, Perrot A, Quach H, Richter J, Spicka I, Yong K, Richardson P
ANN HEMATOL. 2022;101(10):2123-2137.

Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: interim analysis of the GMMG-CONCEPT trial
Leypoldt L, Besemer B, Asemissen A, Hänel M, Blau I, Görner M, Ko Y, Reinhardt H, Staib P, Mann C, Lutz R, Munder M, Graeven U, Peceny R, Salwender H, Jauch A, Zago M, Benner A, Tichy D, Bokemeyer C, Goldschmidt H, Weisel K
LEUKEMIA. 2022;36(3):885-888.

Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial
Lonial S, Popat R, Hulin C, Jagannath S, Oriol A, Richardson P, Facon T, Weisel K, Larsen J, Minnema M, Abdallah A, Badros A, Knop S, Stadtmauer E, Cheng Y, Amatangelo M, Chen M, Nguyen T, Amin A, Peluso T, van de Donk N
LANCET HAEMATOL. 2022;9(11):e822-e832.

Comparative effectiveness of ciltacabtagene autoleucel in CARTITUDE-1 versus physician's choice of therapy in the Flatiron Health multiple myeloma cohort registry for the treatment of patients with relapsed or refractory multiple myeloma
Martin T, Krishnan A, Yong K, Weisel K, Mehra M, Nair S, Qi K, Londhe A, Diels J, Crivera C, Jackson C, Olyslager Y, Vogel M, Schecter J, Banerjee A, Valluri S, Usmani S, Berdeja J, Jagannath S
EJHaem. 2022;3(1):97-108.

LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma
Mateos M, Weisel K, De Stefano V, Goldschmidt H, Delforge M, Mohty M, Cavo M, Vij R, Lindsey-Hill J, Dytfeld D, Angelucci E, Perrot A, Benjamin R, van de Donk N, Ocio E, Scheid C, Gay F, Roeloffzen W, Rodriguez-Otero P, Broijl A, Potamianou A, Sakabedoyan C, Semerjian M, Keim S, Strulev V, Schecter J, Vogel M, Wapenaar R, Nesheiwat T, San-Miguel J, Sonneveld P, Einsele H, Moreau P
LEUKEMIA. 2022;36(5):1371-1376.

COVID-19 and Adult Acute Leukemia: Our Knowledge in Progress
Modemann F, Ghandili S, Schmiedel S, Weisel K, Bokemeyer C, Fiedler W
CANCERS. 2022;14(15):.

COVID-19 and seasonal influenza: a comparative analysis in patients with hematological malignancies
Modemann F, Niederwieser C, Weisel K, Bokemeyer C, Fiedler W, Ghandili S
LEUKEMIA LYMPHOMA. 2022;63(3):664-671.

CD38-specific nanobodies allow in vivo imaging of multiple myeloma under daratumumab therapy
Pape L, Hambach J, Gebhardt A, Rissiek B, Stähler T, Tode N, Khan C, Weisel K, Adam G, Koch-Nolte F, Bannas P
FRONT IMMUNOL. 2022;13:.

Patients With Multiple Myeloma or Monoclonal Gammopathy of Undetermined Significance
Piechotta V, Skoetz N, Engelhardt M, Einsele H, Goldschmidt H, Scheid C
DTSCH ARZTEBL INT. 2022;119(14):253-260.

Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: a subanalysis of OPTIMISMM by clinical characteristics
Richardson P, Schjesvold F, Weisel K, Moreau P, Anderson L, White D, Rodriguez-Otero P, Sonneveld P, Engelhardt M, Jenner M, Corso A, Dürig J, Pavic M, Salomo M, Beksac M, Oriol A, Lindsay J, Liberati A, Galli M, Robak P, Larocca A, Yagci M, Vural F, Kanate A, Jiang R, Grote L, Peluso T, Dimopoulos M
EUR J HAEMATOL. 2022;108(1):73-83.

Risk factors for poor humoral response to primary and booster SARS-CoV-2 vaccination in hematologic and oncological outpatients-COVIDOUT study
Schönlein M, Wrage V, Ghandili S, Mellinghoff S, Brehm T, Leypoldt L, Utz N, Schrader R, Alsdorf W, Börschel N, Bußmann L, Schönrock M, Perlick D, Schön G, Verpoort K, Lütgehetmann M, Schulze Zur Wiesch J, Weisel K, Bokemeyer C, Schafhausen P, Sinn M
CANCER CELL. 2022;40(6):581-583.

MCT1 is a Predictive Marker for Lenalidomide Maintenance Therapy in Multiple Myeloma
Stroh J, Seckinger A, Heider M, Rudelius M, Eichner R, Schick M, Slawska J, Emde M, Salwender H, Bertsch U, Goldschmidt H, Weisel K, Scheid C, Keller U, Hose D, Bassermann F
BLOOD ADV. 2022;6(2):515-520.

Matching-Adjusted Indirect Treatment Comparison to Assess the Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 Versus Belantamab Mafodotin in DREAMM-2, Selinexor-Dexamethasone in STORM Part 2, and Melphalan Flufenamide-Dexamethasone in HORIZON for the Treatment of Patients With Triple-Class Exposed Relapsed or Refractory Multiple Myeloma
Weisel K, Krishnan A, Schecter J, Vogel M, Jackson C, Deraedt W, Yeh T, Banerjee A, Yalniz F, Nesheiwat T, Van Sanden S, Diels J, Valluri S, Usmani S, Berdeja J, Jagannath S, Martin T
CL LYMPH MYELOM LEUK. 2022;22(9):690-701.

Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 vs Physician's Choice of Therapy in the Long-Term Follow-Up of POLLUX, CASTOR, and EQUULEUS Clinical Trials for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Weisel K, Martin T, Krishnan A, Jagannath S, Londhe A, Nair S, Diels J, Vogel M, Schecter J, Banerjee A, Berdeja J, Nesheiwat T, Garrett A, Qi K, Valluri S, Usmani S, Yong K
CLIN DRUG INVEST. 2022;42(1):29-41.

Carfilzomib 56 mg/m2 twice-weekly in combination with dexamethasone and daratumumab (KdD) versus daratumumab in combination with bortezomib and dexamethasone (DVd): a matching-adjusted indirect treatment comparison
Weisel K, Nooka A, Terpos E, Spencer A, Goldschmidt H, Dirnberger F, DeCosta L, Yusuf A, Kumar S
LEUKEMIA LYMPHOMA. 2022;63(8):1887-1896.

Real-world study on adoption of standard-of-care for transplant-eligible newly diagnosed multiple myeloma patients between 2017 and 2020/2021 across France, Germany, Spain, and Italy
Weisel K, Wadlund A, Gungor G, Dergarabetian E, Pacheco C, Masurkar N, Rodriguez-Otero P
EUR J HAEMATOL. 2022;109(4):388-397.

Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR
Avet-Loiseau H, San-Miguel J, Casneuf T, Iida S, Lonial S, Usmani S, Spencer A, Moreau P, Plesner T, Weisel K, Ukropec J, Chiu C, Trivedi S, Amin H, Krevvata M, Ramaswami P, Qin X, Qi M, Sun S, Qi M, Kobos R, Bahlis N
J CLIN ONCOL. 2021;39(10):1139-1149.

Selective elimination of immunosuppressive T cells in patients with multiple myeloma
Awwad M, Mahmoud A, Bruns H, Echchannaoui H, Kriegsmann K, Lutz R, Raab M, Bertsch U, Munder M, Jauch A, Weisel K, Maier B, Weinhold N, Salwender H, Eckstein V, Hänel M, Fenk R, Dürig J, Brors B, Benner A, Müller-Tidow C, Goldschmidt H, Hundemer M
LEUKEMIA. 2021;35(9):2602-2615.

Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma
Baertsch M, Mai E, Hielscher T, Bertsch U, Salwender H, Munder M, Fuhrmann S, Dührsen U, Brossart P, Neben K, Schlenzka J, Kunz C, Raab M, Hillengaß J, Jauch A, Seckinger A, Hose D, Luntz S, Sonneveld P, Lokhorst H, Martin H, Goerner M, Hoffmann M, Lindemann H, Bernhard H, Blau I, Scheid C, Besemer B, Weisel K, Hänel M, Dürig J, Goldschmidt H
BLOOD CANCER J. 2021;11(1):1.

Bone Marrow-Resident Vδ1 T Cells Co-express TIGIT With PD-1, TIM-3 or CD39 in AML and Myeloma
Brauneck F, Weimer P, Schulze zur Wiesch J, Weisel K, Leypoldt L, Vohwinkel G, Fritzsche B, Bokemeyer C, Wellbrock J, Fiedler W
FRONT MED-LAUSANNE. 2021;8:763773.

Evaluation of Cardiac Repolarization in the Randomized Phase 2 Study of Intermediate- or High-Risk Smoldering Multiple Myeloma Patients Treated with Daratumumab Monotherapy
Chari A, Munder M, Weisel K, Jenner M, Bygrave C, Petrucci M, Boccadoro M, Cavo M, van de Donk N, Turgut M, Demirkan F, Karadogan I, Libby E, Kleiman R, Kuppens S, Bandekar R, Neff T, Heuck C, Qi M, Clemens P, Goldschmidt H
ADV THER. 2021;38(2):1328-1341.

Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US
Davies F, Rifkin R, Costello C, Morgan G, Usmani S, Abonour R, Palumbo A, Romanus D, Hajek R, Terpos E, Cherepanov D, Stull D, Huang H, Leleu X, Berdeja J, Lee H, Weisel K, Thompson M, Boccadoro M, Zonder J, Cook G, Puig N, Vela-Ojeda J, Farrelly E, Raju A, Blazer M, Chari A
ANN HEMATOL. 2021;100(9):2325-2337.

Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse
Dimopoulos M, Weisel K, Moreau P, Anderson L, White D, San-Miguel J, Sonneveld P, Engelhardt M, Jenner M, Corso A, Dürig J, Pavic M, Salomo M, Casal E, Srinivasan S, Yu X, Nguyen T, Biyukov T, Peluso T, Richardson P
LEUKEMIA. 2021;35(6):1722-1731.

Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial
Facon T, Kumar S, Plesner T, Orlowski R, Moreau P, Bahlis N, Basu S, Nahi H, Hulin C, Quach H, Goldschmidt H, O'Dwyer M, Perrot A, Venner C, Weisel K, Mace J, Raje N, Tiab M, Macro M, Frenzel L, Leleu X, Ahmadi T, Wang J, Van Rampelbergh R, Uhlar C, Tromp B, Delioukina M, Vermeulen J, Usmani S
LANCET ONCOL. 2021;22(11):1582-1596.

Post-Vaccination Anti-SARS-CoV-2-Antibody Response in Patients with Multiple Myeloma Correlates with Low CD19+ B-Lymphocyte Count and Anti-CD38 Treatment
Ghandili S, Schönlein M, Lütgehetmann M, Wiesch J, Becher H, Bokemeyer C, Sinn M, Weisel K, Leypoldt L
CANCERS. 2021;13(15):.

Lymphocytopenia and Anti-CD38 Directed Treatment Impact the Serological SARS-CoV-2 Response after Prime Boost Vaccination in Patients with Multiple Myeloma
Ghandili S, Schönlein M, Wiessner C, Becher H, Lütgehetmann M, Brehm T, Wiesch J, Bokemeyer C, Sinn M, Weisel K, Leypoldt L
J CLIN MED. 2021;10(23):.

Current Treatment Approaches to Newly Diagnosed Multiple Myeloma
Ghandili S, Weisel K, Bokemeyer C, Leypoldt L
ONCOL RES TREAT. 2021;44(12):690-699.

Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE
Goldschmidt H, Baertsch M, Schlenzka J, Becker N, Habermehl C, Hielscher T, Raab M, Hillengass J, Sauer S, Müller-Tidow C, Luntz S, Jauch A, Hose D, Seckinger A, Brossart P, Goerner M, Klein S, Schmidt-Hieber M, Reimer P, Graeven U, Fenk R, Haenel M, Martin H, Lindemann H, Scheid C, Nogai A, Salwender H, Noppeney R, Besemer B, Weisel K
LEUKEMIA. 2021;35(4):1134-1144.

Ixazomib-lenalidomide-dexamethasone in routine clinical practice:effectiveness in relapsed/refractory multiple myeloma
Hájek R, Minařík J, Straub J, Pour L, Jungova A, Berdeja J, Boccadoro M, Brozova L, Spencer A, Rhee F, Vela-Ojeda J, Thompson M, Abonour R, Chari A, Cook G, Costello C, Davies F, Hungria V, Lee H, Leleu X, Puig N, Rifkin R, Terpos E, Usmani S, Weisel K, Zonder J, Bařinová M, Kuhn M, Šilar J, Čápková L, Galvez K, Lu J, Elliott J, Stull D, Ren K, Maisnar V
FUTURE ONCOL. 2021;17(19):2499-2512.

Health-related quality of life maintained over time in patients with relapsed or refractory multiple myeloma treated with daratumumab in combination with bortezomib and dexamethasone: results from the phase III CASTOR trial
Hungria V, Beksac M, Weisel K, Nooka A, Masszi T, Spicka I, Munder M, Mateos M, Mark T, Qi M, Qin X, Fastenau J, Spencer A, Sonneveld P, Garvin W, Renaud T, Gries K
BRIT J HAEMATOL. 2021;193(3):561-569.

Prognostic Impact of Serum Free Light Chain Ratio Normalization in Patients with Multiple Myeloma Treated within the GMMG-MM5 Trial
Klein E, Tichy D, Salwender H, Mai E, Duerig J, Weisel K, Benner A, Bertsch U, Akhavanpoor M, Besemer B, Munder M, Lindemann H, Hose D, Seckinger A, Luntz S, Jauch A, Elmaagacli A, Fuhrmann S, Brossart P, Goerner M, Bernhard H, Raab M, Blau I, Haenel M, Scheid C, Goldschmidt H, On Behalf Of The German-Speaking Myeloma Multicenter Group Gmmg
CANCERS. 2021;13(19):4856.

56/m mit Rückenschmerzen und Konzentrationsstörungen
Leypoldt L, Weisel K
ONKOLOGE. 2021;2021(27 supplement issue 1):27-32.

Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study
Lonial S, Lee H, Badros A, Trudel S, Nooka A, Chari A, Abdallah A, Callander N, Sborov D, Suvannasankha A, Weisel K, Voorhees P, Womersley L, Baron J, Piontek T, Lewis E, Opalinska J, Gupta I, Cohen A
CANCER-AM CANCER SOC. 2021;127(22):4198-4212.

Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network
Ludwig H, Boccadoro M, Moreau P, San-Miguel J, Cavo M, Pawlyn C, Zweegman S, Facon T, Driessen C, Hajek R, Dimopoulos M, Gay F, Avet-Loiseau H, Terpos E, Zojer N, Mohty M, Mateos M, Einsele H, Delforge M, Caers J, Weisel K, Jackson G, Garderet L, Engelhardt M, van de Donk N, Leleu X, Goldschmidt H, Beksac M, Nijhof I, Abildgaard N, Bringhen S, Sonneveld P
LEUKEMIA. 2021;35(1):31-44.

COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network
Ludwig H, Sonneveld P, Facon T, San-Miguel J, Avet-Loiseau H, Mohty M, Mateos M, Moreau P, Cavo M, Pawlyn C, Zweegman S, Engelhardt M, Driessen C, Cook G, Dimopoulos M, Gay F, Einsele H, Delforge M, Caers J, Weisel K, Jackson G, Garderet L, van de Donk N, Leleu X, Goldschmidt H, Beksac M, Nijhof I, Schreder M, Abildgaard N, Hajek R, Zojer N, Kastritis E, Broijl A, Schjesvold F, Boccadoro M, Terpos E
LANCET HAEMATOL. 2021;8(12):e934-e946.

Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age
Mai E, Miah K, Bertsch U, Dürig J, Scheid C, Weisel K, Kunz C, Munder M, Lindemann H, Merz M, Hose D, Jauch A, Seckinger A, Luntz S, Sauer S, Fuhrmann S, Brossart P, Elmaagacli A, Goerner M, Bernhard H, Hoffmann M, Raab M, Blau I, Hänel M, Benner A, Salwender H, Goldschmidt H
LEUKEMIA. 2021;35(3):809-822.

Front-line daratumumab-VTd versus standard-of-care in ASCT-eligible multiple myeloma: matching-adjusted indirect comparison
Moreau P, Hebraud B, Facon T, Leleu X, Hulin C, Hashim M, Hu Y, Caillot D, Benboubker L, Zweegman S, Merz M, Weisel K, Salwender H, Mai E, Goldschmidt H, Bertsch U, Vanquickelberghe V, Kampfenkel T, Boer C, Krotneva S, Proskorovsky I, He J, Lam A, Lee C, Cote S, Sonneveld P
IMMUNOTHERAPY-UK. 2021;13(2):143-154.

Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group
Moreau P, Kumar S, San Miguel J, Davies F, Zamagni E, Bahlis N, Ludwig H, Mikhael J, Terpos E, Schjesvold F, Martin T, Yong K, Durie B, Facon T, Jurczyszyn A, Sidana S, Raje N, van de Donk N, Lonial S, Cavo M, Kristinsson S, Lentzsch S, Hajek R, Anderson K, João C, Einsele H, Sonneveld P, Engelhardt M, Fonseca R, Vangsted A, Weisel K, Baz R, Hungria V, Berdeja J, Leal da Costa F, Maiolino A, Waage A, Vesole D, Ocio E, Quach H, Driessen C, Bladé J, Leleu X, Riva E, Bergsagel P, Hou J, Chng W, Mellqvist U, Dytfeld D, Harousseau J, Goldschmidt H, Laubach J, Munshi N, Gay F, Beksac M, Costa L, Kaiser M, Hari P, Boccadoro M, Usmani S, Zweegman S, Holstein S, Harrison S, Nahi H, Cook G, Mateos M, Rajkumar S, Dimopoulos M, Richardson P
LANCET ONCOL. 2021;22(3):e105-e118.

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
Munshi N, Anderson L, Shah N, Madduri D, Berdeja J, Lonial S, Raje N, Lin Y, Siegel D, Oriol A, Moreau P, Yakoub-Agha I, Delforge M, Cavo M, Einsele H, Goldschmidt H, Weisel K, Rambaldi A, Reece D, Petrocca F, Massaro M, Connarn J, Kaiser S, Patel P, Huang L, Campbell T, Hege K, San-Miguel J
NEW ENGL J MED. 2021;384(8):705-716.

Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design
Nooka A, Weisel K, van de Donk N, Routledge D, Otero P, Song K, Quach H, Callander N, Minnema M, Trudel S, Jackson N, Ahlers C, Im E, Cheng S, Smith L, Hareth N, Ferron-Brady G, Brouch M, de Oca R, Paul S, Holkova B, Gupta I, Kremer B, Richardson P
FUTURE ONCOL. 2021;17(16):1987-2003.

Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA Trial
Perrot A, Facon T, Plesner T, Usmani S, Kumar S, Bahlis N, Hulin C, Orlowski R, Nahi H, Mollee P, Ramasamy K, Roussel M, Jaccard A, Delforge M, Karlin L, Arnulf B, Chari A, He J, Ho K, Van Rampelbergh R, Uhlar C, Wang J, Kobos R, Gries K, Fastenau J, Weisel K
J CLIN ONCOL. 2021;39(3):227-237.

Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy
Quach H, Nooka A, Samoylova O, Venner C, Kim K, Facon T, Spencer A, Usmani S, Grosicki S, Suzuki K, Delimpasi S, Weisel K, Obreja M, Zahlten-Kumeli A, Mateos M
BRIT J HAEMATOL. 2021;194(4):784-788.

Monoclonal Antibodies and Antibody Drug Conjugates in Multiple Myeloma
Radocha J, van de Donk N, Weisel K
CANCERS. 2021;13(7):1551.

Improving outcomes for patients with relapsed multiple myeloma: Challenges and considerations of current and emerging treatment options
Ramasamy K, Gay F, Weisel K, Zweegman S, Mateos M, Richardson P
BLOOD REV. 2021;49:100808.

Matching adjusted indirect comparisons of efficacy outcomes for idecabtagene vicleucel (ide-cel, bb2121) versus selinexor + dexamethasone and belantamab mafodotin in relapsed and refractory multiple myeloma
Rodriguez-Otero P, Ayers D, Cope S, Davies F, Delforge M, Mojebi A, Jansen J, Weisel K, Hege K, Dhanasiri S
LEUKEMIA LYMPHOMA. 2021;62(10):2482-2491.

Long-term follow-up of subcutaneous versus intravenous bortezomib during induction therapy for newly diagnosed multiple myeloma treated within the GMMG-MM5 Phase III Trial
Salwender H, Elmaagacli A, Merz M, Miah K, Benner A, Haenel M, Jehn C, Mai E, Bertsch U, Blau I, Scheid C, Hose D, Seckinger A, Jauch A, Raab M, Luntz S, Besemer B, Munder M, Brossart P, Fuhrmann S, Lindemann H, Weisel K, Duerig J, Goldschmidt H
LEUKEMIA. 2021;35(10):3007-3011.

Health-related quality of life outcomes from the CANDOR study in patients with relapsed or refractory multiple myeloma
Siegel D, Weisel K, Zahlten-Kumeli A, Medhekar R, Ding B, Leleu X
LEUKEMIA LYMPHOMA. 2021;62(12):3002-3010.

Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life
Terpos E, Mikhael J, Hajek R, Chari A, Zweegman S, Lee H, Mateos M, Larocca A, Ramasamy K, Kaiser M, Cook G, Weisel K, Costello C, Elliott J, Palumbo A, Usmani S
BLOOD CANCER J. 2021;11(2):40.

Outcome of a Real-World Patient Cohort with Secondary CNS Lymphoma Treated with High-Intensity Chemoimmunotherapy and Autologous Stem Cell Transplantation
Thiele B, Binder M, Schliffke S, Frenzel C, Dierlamm J, Wass M, Weisel K, Bokemeyer C, Janjetovic S
ONCOL RES TREAT. 2021;44(7-8):375-381.

Efficacy and safety profile of deep responders to carfilzomib-based therapy: a subgroup analysis from ASPIRE and ENDEAVOR
Weisel K, Mateos M, Gay F, Delforge M, Cook G, Szabo Z, Desgraz R, DeCosta L, Moreau P
LEUKEMIA. 2021;35(6):1732-1744.

Mass spectrometry-based identification of a B-cell maturation antigen-derived T-cell epitope for antigen-specific immunotherapy of multiple myeloma
Bilich T, Nelde A, Bauer J, Walz S, Roerden M, Salih H, Weisel K, Besemer B, Marcu A, Lübke M, Schuhmacher J, Neidert M, Rammensee H, Stevanović S, Walz J
BLOOD CANCER J. 2020;10(2):24.

Clinical Features Associated with COVID-19 Outcome in MM: First Results from International Myeloma Society Dataset
Chari A, Samur M, Martinez-Lopez J, Cook G, Biran N, Yong K, Hungria V, Engelhardt M, Gay F, Garcia-Feria A, Oliva S, Oostvogels R, Gozzetti A, Rosenbaum C, Kumar S, Stadtmauer E, Einsele H, Beksac M, Weisel K, Anderson K, Mateos M, Moreau P, San Miguel J, Munshi N, Avet-Loiseau H
BLOOD. 2020.

Critical Appraisal of Published Indirect Comparisons and Network Meta-Analyses of Competing Interventions for Multiple Myeloma
Cope S, Toor K, Popoff E, Fonseca R, Landgren O, Mateos M, Weisel K, Jansen J
VALUE HEALTH. 2020;23(4):441-450.

Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma
Dimopoulos M, Jakubowiak A, McCarthy P, Orlowski R, Attal M, Bladé J, Goldschmidt H, Weisel K, Ramasamy K, Zweegman S, Spencer A, Huang J, Lu J, Sunami K, Iida S, Chng W, Holstein S, Rocci A, Skacel T, Labotka R, Palumbo A, Anderson K
BLOOD CANCER J. 2020;10(2):17.

Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study
Dimopoulos M, Lonial S, White D, Moreau P, Weisel K, San-Miguel J, Shpilberg O, Grosicki S, Špička I, Walter-Croneck A, Magen H, Mateos M, Belch A, Reece D, Beksac M, Spencer A, Oakervee H, Orlowski R, Taniwaki M, Röllig C, Einsele H, Matsumoto M, Wu K, Anderson K, Jou Y, Ganetsky A, Singhal A, Richardson P
BLOOD CANCER J. 2020;10(9):91.

Once- versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 A.R.R.O.W. study subgroup analysis
Dimopoulos M, Niesvizky R, Weisel K, Siegel D, Hajek R, Mateos M, Cavo M, Huang M, Zahlten-Kumeli A, Moreau P
BLOOD CANCER J. 2020;10(3):35.

Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study
Dimopoulos M, Quach H, Mateos M, Landgren O, Leleu X, Siegel D, Weisel K, Yang H, Klippel Z, Zahlten-Kumeli A, Usmani S
LANCET. 2020;396(10245):186-197.

Efficacy and safety of carfilzomib-based regimens in frail patients with relapsed and/or refractory multiple myeloma
Facon T, Niesvizky R, Mateos M, Siegel D, Rosenbaum C, Bringhen S, Weisel K, Ho P, Ludwig H, Kumar S, Wang K, Obreja M, Yang Z, Klippel Z, Mezzi K, Goldrick A, Tekle C, Dimopoulos M
BLOOD ADV. 2020;4(21):5449-5459.

Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials
Gavriatopoulou M, Chari A, Chen C, Bahlis N, Vogl D, Jakubowiak A, Dingli D, Cornell R, Hofmeister C, Siegel D, Berdeja J, Reece D, White D, Lentzsch S, Gasparetto C, Huff C, Jagannath S, Baz R, Nooka A, Richter J, Abonour R, Parker T, Yee A, Moreau P, Lonial S, Tuchman S, Weisel K, Mohty M, Choquet S, Unger T, Li K, Chai Y, Li L, Shah J, Shacham S, Kauffman M, Dimopoulos M
LEUKEMIA. 2020;34(9):2430-2440.

Challenges in treatment of patients with acute leukemia and COVID-19: a series of 12 patients
Ghandili S, Pfefferle S, Roedl K, Sonnemann P, Karagiannis P, Boenisch O, Kluge S, Schmiedel S, Ittrich H, Rohde H, Lütgehetmann M, Weisel K, Bokemeyer C, Wichmann D, Fiedler W, Jarczak D, Modemann F
BLOOD ADV. 2020;4(23):5936-5941.

Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant maintenance in multiple myeloma
Goldschmidt H, Dimopoulos M, Rajkumar S, Weisel K, Moreau P, Chng W, Mikala G, Cavo M, Ramasamy K, Suryanarayan K, Teng Z, Labotka R, Mateos M
LEUKEMIA. 2020;34(11):3019-3027.

Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial
Goldschmidt H, Mai E, Dürig J, Scheid C, Weisel K, Kunz C, Bertsch U, Hielscher T, Merz M, Munder M, Lindemann H, Hügle-Dörr B, Tichy D, Giesen N, Hose D, Seckinger A, Huhn S, Luntz S, Jauch A, Elmaagacli A, Rabold B, Fuhrmann S, Brossart P, Goerner M, Bernhard H, Hoffmann M, Hillengass J, Raab M, Blau I, Hänel M, Salwender H
LEUKEMIA. 2020;34(7):1853-1865.

Autologous stem cell transplantation in multiple myeloma patients: utilization patterns and hospital effects
Jansen L, Merz M, Engelhardt M, Weisel K, Scheid C, Straka C, Langer C, Salwender H, Einsele H, Kröger N, Beelen D, Dreger P, Goldschmidt H, Brenner H
LEUKEMIA LYMPHOMA. 2020;61(10):2365-2374.

Intensive Care Outcomes of Patients after High Dose Chemotherapy and Subsequent Autologous Stem Cell Transplantation: A Retrospective, Single Centre Analysis
Karagiannis P, Sänger L, Alsdorf W, Weisel K, Fiedler W, Kluge S, Wichmann D, Bokemeyer C, Fuhrmann V
CANCERS. 2020;12(6):.

Comparison of NGS and MFC Methods: Key Metrics in Multiple Myeloma MRD Assessment
Kriegsmann K, Hundemer M, Hofmeister-Mielke N, Reichert P, Manta C, Awwad M, Sauer S, Bertsch U, Besemer B, Fenk R, Hänel M, Munder M, Weisel K, Blau I, Neubauer A, Müller-Tidow C, Raab M, Goldschmidt H, Huhn S, For The German-Speaking Myeloma Multicenter Group Gmmg
CANCERS. 2020;12(8):.

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study
Lonial S, Lee H, Badros A, Trudel S, Nooka A, Chari A, Abdallah A, Callander N, Lendvai N, Sborov D, Suvannasankha A, Weisel K, Karlin L, Libby E, Arnulf B, Facon T, Hulin C, Kortüm K, Rodríguez-Otero P, Usmani S, Hari P, Baz R, Quach H, Moreau P, Voorhees P, Gupta I, Hoos A, Zhi E, Baron J, Piontek T, Lewis E, Jewell R, Dettman E, Popat R, Esposti S, Opalinska J, Richardson P, Cohen A
LANCET ONCOL. 2020;21(2):207-221.

Quality of life in patients with relapsed/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib maintenance therapy and comparison to the general population
Ludwig H, Pönisch W, Knop S, Egle A, Hinke A, Schreder M, Lechner D, Hajek R, Gunsilius E, Petzer A, Weisel K, Niederwieser D, Einsele H, Willenbacher W, Rumpold H, Pour L, Jelinek T, Krenosz K, Meckl A, Nolte S, Melchardt T, Greil R, Zojer N
LEUKEMIA LYMPHOMA. 2020;61(2):377-386.

Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies
Mateos M, Spencer A, Nooka A, Pour L, Weisel K, Cavo M, Laubach J, Cook G, Iida S, Benboubker L, Usmani S, Yoon S, Bahlis N, Chiu C, Ukropec J, Schecter J, Qin X, O' Rourke L, Dimopoulos M
HAEMATOLOGICA. 2020;105(2):468-477.

MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1-2a trial
Raab M, Engelhardt M, Blank A, Goldschmidt H, Agis H, Blau I, Einsele H, Ferstl B, Schub N, Röllig C, Weisel K, Winderlich M, Griese J, Härtle S, Weirather J, Jarutat T, Peschel C, Chatterjee M
LANCET HAEMATOL. 2020;7(5):e381-e394.

Relative efficacy of treatment options in transplant-ineligible newly diagnosed multiple myeloma: results from a systematic literature review and network meta-analysis
Ramasamy K, Dhanasiri S, Thom H, Buchanan V, Robinson S, D'Souza V, Weisel K
LEUKEMIA LYMPHOMA. 2020;61(3):668-679.

Comparison of three different serum-free light-chain assays-implications on diagnostic and therapeutic monitoring of multiple myeloma
Schieferdecker A, Hörber S, Ums M, Besemer B, Bokemeyer C, Peter A, Weisel K
BLOOD CANCER J. 2020;10(1):2.

First-in-Human Phase I Study of ABBV-838, an Antibody-Drug Conjugate Targeting SLAMF7/CS1 in Patients with Relapsed and Refractory Multiple Myeloma
Vij R, Nath R, Afar D, Mateos M, Berdeja J, Raab M, Guenther A, Martinez-Lopez J, Jakubowiak A, Leleu X, Weisel K, Wong S, Gulbranson S, Sheridan J, Reddy A, Paiva B, Singhal A, San-Miguel J, Moreau P
CLIN CANCER RES. 2020;26(10):2308-2317.

Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma
Weisel K, Dimopoulos M, Moreau P, Yagci M, Larocca A, Kanate A, Vural F, Cascavilla N, Basu S, Johnson P, Byeff P, Hus M, Rodríguez-Otero P, Muelduer E, Anttila P, Hayden P, Krauth M, Lucio P, Ben-Yehuda D, Mendeleeva L, Guo S, Yu X, Grote L, Biyukov T, Dhanasiri S, Richardson P
LEUKEMIA LYMPHOMA. 2020;61(8):1850-1859.

Health-related quality of life of carfilzomib- and daratumumab-based therapies in patients with relapsed/refractory multiple myeloma, based on German benefit assessment data
Weisel K, Ludwig H, Rieth A, Lebioda A, Goldschmidt H
QUAL LIFE RES. 2020;29(1):69-79.

Carfilzomib and dexamethasone versus eight cycles of bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma: an indirect comparison using data from the phase 3 ENDEAVOR and CASTOR trials
Weisel K, Majer I, DeCosta L, Oriol A, Goldschmidt H, Ludwig H, Campioni M, Szabo Z, Dimopoulos M
LEUKEMIA LYMPHOMA. 2020;61(1):37-46.

Implications of SARS-CoV-2 Infection and COVID-19 Crisis on Clinical Cancer Care: Report of the University Cancer Center Hamburg: Report of the University Cancer Center Hamburg
Weisel K, Morgner-Miehlke A, Petersen C, Fiedler W, Block A, Schafhausen P, Knobloch J, Bokemeyer C
ONCOL RES TREAT. 2020;43(6):307-313.

Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk
Weisel K, Spencer A, Lentzsch S, Avet-Loiseau H, Mark T, Spicka I, Masszi T, Lauri B, Levin M, Bosi A, Hungria V, Cavo M, Lee J, Nooka A, Quach H, Munder M, Lee C, Barreto W, Corradini P, Min C, Chanan-Khan A, Horvath N, Capra M, Beksac M, Ovilla R, Jo J, Shin H, Sonneveld P, Casneuf T, DeAngelis N, Amin H, Ukropec J, Kobos R, Mateos M
J HEMATOL ONCOL. 2020;13(1):115.

Early M-protein Dynamics Predicts Progression-Free Survival in Patients With Relapsed/Refractory Multiple Myeloma
Yan X, Xu X, Weisel K, Mateos M, Sonneveld P, Dimopoulos M, Usmani S, Bahlis N, Puchalski T, Ukropec J, Bellew K, Ming Q, Sun S, Zhou H
CTS-CLIN TRANSL SCI. 2020;13(6):1345-1354.

Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma
Chari A, Vogl D, Gavriatopoulou M, Nooka A, Yee A, Huff C, Moreau P, Dingli D, Cole C, Lonial S, Dimopoulos M, Stewart A, Richter J, Vij R, Tuchman S, Raab M, Weisel K, Delforge M, Cornell R, Kaminetzky D, Hoffman J, Costa L, Parker T, Levy M, Schreder M, Meuleman N, Frenzel L, Mohty M, Choquet S, Schiller G, Comenzo R, Engelhardt M, Illmer T, Vlummens P, Doyen C, Facon T, Karlin L, Perrot A, Podar K, Kauffman M, Shacham S, Li L, Tang S, Picklesimer C, Saint-Martin J, Crochiere M, Chang H, Parekh S, Landesman Y, Shah J, Richardson P, Jagannath S
NEW ENGL J MED. 2019;381(8):727-738.

INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myeloma
Costello C, Davies F, Cook G, Vela-Ojeda J, Omel J, Rifkin R, Berdeja J, Puig N, Usmani S, Weisel K, Zonder J, Terpos E, Spencer A, Leleu X, Boccadoro M, Thompson M, Romanus D, Stull D, Hungria V
FUTURE ONCOL. 2019;15(13):1411-1428.

Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial
Dimopoulos M, Gay F, Schjesvold F, Beksac M, Hajek R, Weisel K, Goldschmidt H, Maisnar V, Moreau P, Min C, Pluta A, Chng W, Kaiser M, Zweegman S, Mateos M, Spencer A, Iida S, Morgan G, Suryanarayan K, Teng Z, Skacel T, Palumbo A, Dash A, Gupta N, Labotka R, Rajkumar S
LANCET. 2019;393(10168):253-264.

Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
Facon T, Kumar S, Plesner T, Orlowski R, Moreau P, Bahlis N, Basu S, Nahi H, Hulin C, Quach H, Goldschmidt H, O'Dwyer M, Perrot A, Venner C, Weisel K, Mace J, Raje N, Attal M, Tiab M, Macro M, Frenzel L, Leleu X, Ahmadi T, Chiu C, Wang J, Van Rampelbergh R, Uhlar C, Kobos R, Qi M, Usmani S
NEW ENGL J MED. 2019;380(22):2104-2115.

Development of an Initial Conceptual Model of Multiple Myeloma to Support Clinical and Health Economics Decision Making
Gonzalez-McQuire S, Dimopoulos M, Weisel K, Bouwmeester W, Hájek R, Campioni M, Bennison C, Xu W, Pantiri K, Hensen M, Terpos E, Knop S
MDM POLICY PRACT. 2019;4(1):2381468318814253.

Summary of the Second Annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling
Holstein S, Ye J, Howard A, Bhutani M, Gormley N, Hahn T, Hillengass J, Krishnan A, Landgren C, Munshi N, Oliva S, Owen R, Pasquini M, Puig N, Weinhold N, Weisel K, McCarthy P
BIOL BLOOD MARROW TR. 2019;25(3):e89-e97.

Prospective target assessment and multimodal prediction of survival for personalized and risk-adapted treatment strategies in multiple myeloma in the GMMG-MM5 multicenter trial
Hose D, Beck S, Salwender H, Emde M, Bertsch U, Kunz C, Scheid C, Hänel M, Weisel K, Hielscher T, Raab M, Goldschmidt H, Jauch A, Moreaux J, Seckinger A
J HEMATOL ONCOL. 2019;12(1):65.

High cutoff versus high-flux haemodialysis for myeloma cast nephropathy in patients receiving bortezomib-based chemotherapy (EuLITE): a phase 2 randomised controlled trial
Hutchison C, Cockwell P, Moroz V, Bradwell A, Fifer L, Gillmore J, Jesky M, Storr M, Wessels J, Winearls C, Weisel K, Heyne N, Cook M
LANCET HAEMATOL. 2019;6(4):e217-e228.

Cereblon-binding proteins expression levels correlate with hyperdiploidy in newly diagnosed multiple myeloma patients
Kriegsmann K, Baertsch M, Awwad M, Merz M, Hose D, Seckinger A, Jauch A, Becker N, Benner A, Raab M, Hillengass J, Bertsch U, Dürig J, Salwender H, Hänel M, Fenk R, Munder M, Weisel K, Müller-Tidow C, Goldschmidt H, Hundemer M
BLOOD CANCER J. 2019;9(2):13.

Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma
Ludwig H, Moreau P, Dimopoulos M, Mateos M, Kaiser M, Hajek R, Feng S, Cocks K, Buchanan J, Weisel K
BLOOD CANCER J. 2019;9(3):23.

Ixazomib-Thalidomide-Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma
Ludwig H, Poenisch W, Knop S, Egle A, Schreder M, Lechner D, Hajek R, Gunsilius E, Krenosz K, Petzer A, Weisel K, Niederwieser D, Einsele H, Willenbacher W, Melchardt T, Greil R, Zojer N
BRIT J CANCER. 2019;121(9):751-757.

Bortezomib-based induction therapy with high or low-dose dexamethasone in newly diagnosed, transplant-eligible multiple myeloma
Mai E, Hielscher T, Bertsch U, Schlenzka J, Salwender H, Munder M, Gerecke C, Dührsen U, Brossart P, Neben K, Hillengass J, Raab M, Merz M, Baertsch M, Jauch A, Hose D, Martin H, Lindemann H, Blau I, Scheid C, Weisel K, Goldschmidt H
LEUKEMIA. 2019;33(1):258-261.

Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR
Mateos M, Sonneveld P, Hungria V, Nooka A, Estell J, Barreto W, Corradini P, Min C, Medvedova E, Weisel K, Chiu C, Schecter J, Amin H, Qin X, Ukropec J, Kobos R, Spencer A
CL LYMPH MYELOM LEUK. 2019.

Cystic transformation of focal lesions after therapy is associated with remission but adverse outcome in myeloma
Merz M, Hielscher T, Mai E, Seckinger A, Hose D, Jauch A, Sauer S, Luntz S, Bertsch U, Raab M, Neben K, Salwender H, Blau I, Lindemann H, Dürig J, Scheid C, Haenel M, Weisel K, Weber T, Delorme S, Goldschmidt H, Hillengass J
BLOOD CANCER J. 2019;9(9):71.

Cereblon gene expression and correlation with clinical outcomes in patients with relapsed/refractory multiple myeloma treated with pomalidomide: an analysis of STRATUS
Qian X, Dimopoulos M, Amatangelo M, Bjorklund C, Towfic F, Flynt E, Weisel K, Ocio E, Yu X, Peluso T, Sternas L, Zaki M, Moreau P, Thakurta A
LEUKEMIA LYMPHOMA. 2019;60(2):462-470.

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial
Richardson P, Oriol A, Beksac M, Liberati A, Galli M, Schjesvold F, Lindsay J, Weisel K, White D, Facon T, San Miguel J, Sunami K, O'Gorman P, Sonneveld P, Robak P, Semochkin S, Schey S, Yu X, Doerr T, Bensmaine A, Biyukov T, Peluso T, Zaki M, Anderson K, Dimopoulos M
LANCET ONCOL. 2019;20(6):781-794.

Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma
Salwender H, Bertsch U, Weisel K, Duerig J, Kunz C, Benner A, Blau I, Raab M, Hillengass J, Hose D, Huhn S, Hundemer M, Andrulis M, Jauch A, Seidel-Glaetzer A, Lindemann H, Hensel M, Fronhoffs S, Martens U, Hansen T, Wattad M, Graeven U, Munder M, Fenk R, Haenel M, Scheid C, Goldschmidt H
BMC CANCER. 2019;19(1):504.

Monoklonale Gammopathie unklarer Signifikanz – ein häufiger Nebenbefund: Woran ist zu denken? Was ist zu tun?
Schieferdecker A, Binder M, Weisel K, Bokemeyer C
DEUT MED WOCHENSCHR. 2019;144(14):982-989.

Addition of cyclophosphamide on insufficient response to pomalidomide and dexamethasone: results of the phase II PERSPECTIVE Multiple Myeloma trial
Weisel K, Scheid C, Zago M, Besemer B, Mai E, Haenel M, Duerig J, Munder M, Lindemann H, Seckinger A, Kunz C, Benner A, Hose D, Jauch A, Salwender H, Goldschmidt H
BLOOD CANCER J. 2019;9(4):45.

A comparison of the efficacy of immunomodulatory-free regimens in relapsed or refractory multiple myeloma: a network meta-analysis
Weisel K, Sonneveld P, Spencer A, Beksac M, Rizzo M, Xu Y, Fahrbach K, Gaudig M, Slavcev M, Dearden L, Lam A
LEUKEMIA LYMPHOMA. 2019;60(1):151-162.

The prognostic and predictive value of IKZF1 and IKZF3 expression in T-cells in patients with multiple myeloma
Awwad M, Kriegsmann K, Plaumann J, Benn M, Hillengass J, Raab M, Bertsch U, Munder M, Weisel K, Salwender H, Hänel M, Fenk R, Dürig J, Müller-Tidow C, Goldschmidt H, Hundemer M
ONCOIMMUNOLOGY. 2018;7(10):e1486356.

Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial
Dimopoulos M, Lonial S, Betts K, Chen C, Zichlin M, Brun A, Signorovitch J, Makenbaeva D, Mekan S, Sy O, Weisel K, Richardson P
CANCER-AM CANCER SOC. 2018;124(20):4032-4043.

Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial
Dimopoulos M, Weisel K, van de Donk N, Ramasamy K, Gamberi B, Streetly M, Offidani M, Bridoux F, de la Rubia J, Mateos M, Ardizzoia A, Kueenburg E, Collins S, Di Micco A, Rosettani B, Li Y, Bacon P, Sonneveld P
J CLIN ONCOL. 2018;36(20):2035-2043.

Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma
Facon T, Dimopoulos M, Dispenzieri A, Catalano J, Belch A, Cavo M, Pinto A, Weisel K, Ludwig H, Bahlis N, Banos A, Tiab M, Delforge M, Cavenagh J, Geraldes C, Lee J, Chen C, Oriol A, De La Rubia J, White D, Binder D, Lu J, Anderson K, Moreau P, Attal M, Perrot A, Arnulf B, Qiu L, Roussel M, Boyle E, Manier S, Mohty M, Avet-Loiseau H, Leleu X, Ervin-Haynes A, Chen G, Houck V, Benboubker L, Hulin C
BLOOD. 2018;131(3):301-310.

Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial
Goldschmidt H, Lokhorst H, Mai E, van der Holt B, Blau I, Zweegman S, Weisel K, Vellenga E, Pfreundschuh M, Kersten M, Scheid C, Croockewit S, Raymakers R, Hose D, Potamianou A, Jauch A, Hillengass J, Stevens-Kroef M, Raab M, Broijl A, Lindemann H, Bos G, Brossart P, van Marwijk Kooy M, Ypma P, Duehrsen U, Schaafsma R, Bertsch U, Hielscher T, Jarari L, Salwender H, Sonneveld P
LEUKEMIA. 2018;32(2):383-390.

Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study
Goldschmidt H, Moreau P, Ludwig H, Niesvizky R, Chng W, Joshua D, Weisel K, Spencer A, Orlowski R, Feng S, Iskander K, Dimopoulos M
LEUKEMIA LYMPHOMA. 2018;59(6):1364-1374.

BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling: Summary and Recommendations from the Organizing Committee
Holstein S, Avet-Loiseau H, Hahn T, Ho C, Lohr J, Munshi N, Paiva B, Pasquini M, Tario J, Usmani S, Wallace P, Weisel K, McCarthy P
BIOL BLOOD MARROW TR. 2018;24(4):641-648.

Comparison of qualitative and quantitative CT and MRI parameters for monitoring of longitudinal spine involvement in patients with multiple myeloma
Horger M, Fritz J, Thaiss W, Ditt H, Weisel K, Haap M, Kloth C
SKELETAL RADIOL. 2018;47(3):351-361.

Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network
Ludwig H, Delforge M, Facon T, Einsele H, Gay F, Moreau P, Avet-Loiseau H, Boccadoro M, Hajek R, Mohty M, Cavo M, Dimopoulos M, San-Miguel J, Terpos E, Zweegman S, Garderet L, Mateos M, Cook G, Leleu X, Goldschmidt H, Jackson G, Kaiser M, Weisel K, van de Donk N, Waage A, Beksac M, Mellqvist U, Engelhardt M, Caers J, Driessen C, Bladé J, Sonneveld P
LEUKEMIA. 2018;32(7):1542-1560.

Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma
Merz M, Jauch A, Hielscher T, Bochtler T, Schönland S, Seckinger A, Hose D, Bertsch U, Neben K, Raab M, Hillengass J, Salwender H, Blau I, Lindemann H, Schmidt-Wolf I, Scheid C, Haenel M, Weisel K, Goldschmidt H
BLOOD ADV. 2018;2(1):1-9.

Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study
Moreau P, Mateos M, Berenson J, Weisel K, Lazzaro A, Song K, Dimopoulos M, Huang M, Zahlten-Kumeli A, Stewart A
LANCET ONCOL. 2018;19(7):953-964.

Maintenance and continuous therapy for multiple myeloma
Richardson P, Laubach J, Gandolfi S, Facon T, Weisel K, O'Gorman P
EXPERT REV ANTICANC. 2018;18(8):751-764.

Corrigendum to "Simplified response monitoring criteria for multiple myeloma in patients undergoing therapy with novel agents using computed tomography" [Eur. J. Radiol. 85 (December (12)), 2016, 2195-2199]
Schabel C, Horger M, Kum S, Weisel K, Fritz J, Ioanoviciu S, Bier G
EUR J RADIOL. 2018;103:163.

Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR
Spencer A, Lentzsch S, Weisel K, Avet-Loiseau H, Mark T, Spicka I, Masszi T, Lauri B, Levin M, Bosi A, Hungria V, Cavo M, Lee J, Nooka A, Quach H, Lee C, Barreto W, Corradini P, Min C, Scott E, Chanan-Khan A, Horvath N, Capra M, Beksac M, Ovilla R, Jo J, Shin H, Sonneveld P, Soong D, Casneuf T, Chiu C, Amin H, Qi M, Thiyagarajah P, Sasser A, Schecter J, Mateos M
HAEMATOLOGICA. 2018;103(12):2079-2087.

A meta-analysis of HLA peptidome composition in different hematological entities: entity-specific dividing lines and "pan-leukemia" antigens: entity-specific dividing lines and "pan-leukemia" antigens
Backert L, Kowalewski D, Walz S, Schuster H, Berlin C, Neidert M, Schemionek M, Brümmendorf T, Vucinic V, Niederwieser D, Kanz L, Salih H, Kohlbacher O, Weisel K, Rammensee H, Stevanovic S, Walz J
ONCOTARGET. 2017;8(27):43915-43924.

Cyclophosphamide-based stem cell mobilization in relapsed multiple myeloma patients: A subgroup analysis from the phase III trial ReLApsE
Baertsch M, Schlenzka J, Lisenko K, Krzykalla J, Becker N, Weisel K, Noppeney R, Martin H, Lindemann H, Haenel M, Nogai A, Scheid C, Salwender H, Fenk R, Graeven U, Reimer P, Schmidt-Hieber M, Goerner M, Schmidt-Wolf I, Klein S, Ho A, Goldschmidt H, Wuchter P
EUR J HAEMATOL. 2017;99(1):42-50.

Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR
Chng W, Goldschmidt H, Dimopoulos M, Moreau P, Joshua D, Palumbo A, Facon T, Ludwig H, Pour L, Niesvizky R, Oriol A, Rosiñol L, Suvorov A, Gaidano G, Pika T, Weisel K, Goranova-Marinova V, Gillenwater H, Mohamed N, Feng S, Aggarwal S, Hájek R
LEUKEMIA. 2017;31(6):1368-1374.

Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial
Dimopoulos M, Goldschmidt H, Niesvizky R, Joshua D, Chng W, Oriol A, Orlowski R, Ludwig H, Facon T, Hajek R, Weisel K, Hungria V, Minuk L, Feng S, Zahlten-Kumeli A, Kimball A, Moreau P
LANCET ONCOL. 2017;18(10):1327-1337.

Automated "Bone Subtraction" Image Analysis Software Package for Improved and Faster CT Monitoring of Longitudinal Spine Involvement in Patients with Multiple Myeloma
Horger M, Ditt H, Liao S, Weisel K, Fritz J, Thaiss W, Kaufmann S, Nikolaou K, Kloth C
ACAD RADIOL. 2017;24(5):623-632.

Improved MDCT monitoring of pelvic myeloma bone disease through the use of a novel longitudinal bone subtraction post-processing algorithm
Horger M, Thaiss W, Ditt H, Weisel K, Fritz J, Nikolaou K, Liao S, Kloth C
EUR RADIOL. 2017;27(7):2969-2977.

Circulating tumor cells as a biomarker for response to therapy in multiple myeloma patients treated within the GMMG-MM5 trial
Huhn S, Weinhold N, Nickel J, Pritsch M, Hielscher T, Hummel M, Bertsch U, Huegle-Doerr B, Vogel M, Angermund R, Hänel M, Salwender H, Weisel K, Dürig J, Görner M, Kirchner H, Peter N, Graeven U, Lordick F, Hoffmann M, Reimer P, Blau I, Jauch A, Dembowsky K, Möhler T, Wuchter P, Goldschmidt H
BONE MARROW TRANSPL. 2017;52(8):1194-1198.

Population pharmacokinetics of pomalidomide in patients with relapsed or refractory multiple myeloma with various degrees of impaired renal function
Li Y, Wang X, O'Mara E, Dimopoulos M, Sonneveld P, Weisel K, Matous J, Siegel D, Shah J, Kueenburg E, Sternas L, Cavanaugh C, Zaki M, Palmisano M, Zhou S
CLIN PHARMACOL-ADV A. 2017;9:133-145.

Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup
Ludwig H, Dimopoulos M, Moreau P, Chng W, Goldschmidt H, Hájek R, Facon T, Pour L, Niesvizky R, Oriol A, Rosiñol L, Suvorov A, Gaidano G, Pika T, Weisel K, Goranova-Marinova V, Palumbo A, Gillenwater H, Mohamed N, Aggarwal S, Feng S, Joshua D
LEUKEMIA LYMPHOMA. 2017;58(10):2501-2504.

Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib-dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study
Ludwig H, Weisel K, Petrucci M, Leleu X, Cafro A, Garderet L, Leitgeb C, Foa R, Greil R, Yakoub-Agha I, Zboralski D, Vauléon S, Dümmler T, Beyer D, Kruschinski A, Riecke K, Baumann M, Engelhardt M
LEUKEMIA. 2017;31(4):997-1000.

Longitudinal fluorescence hybridization reveals cytogenetic evolution in myeloma relapsing after autologous transplantation
Merz M, Jauch A, Hielscher T, Mai E, Seckinger A, Hose D, Bertsch U, Neben K, Raab M, Salwender H, Blau I, Lindemann H, Schmidt-Wolf I, Scheid C, Haenel M, Weisel K, Goldschmidt H, Hillengass J
HAEMATOLOGICA. 2017;102(8):1432-1438.

Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis
Moreau P, Dimopoulos M, Richardson P, Siegel D, Cavo M, Corradini P, Weisel K, Delforge M, O'Gorman P, Song K, Chen C, Bahlis N, Oriol A, Hansson M, Kaiser M, Anttila P, Raymakers R, Joao C, Cook G, Sternas L, Biyukov T, Slaughter A, Hong K, Herring J, Yu X, Zaki M, San-Miguel J
EUR J HAEMATOL. 2017;99(3):199-206.

Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study
Moreau P, Joshua D, Chng W, Palumbo A, Goldschmidt H, Hájek R, Facon T, Ludwig H, Pour L, Niesvizky R, Oriol A, Rosiñol L, Suvorov A, Gaidano G, Pika T, Weisel K, Goranova-Marinova V, Gillenwater H, Mohamed N, Aggarwal S, Feng S, Dimopoulos M
LEUKEMIA. 2017;31(1):115-122.

Frequency of expression and generation of T-cell responses against antigens on multiple myeloma cells in patients included in the GMMG-MM5 trial
Schmitt M, Hückelhoven A, Hundemer M, Schmitt A, Lipp S, Emde M, Salwender H, Hänel M, Weisel K, Bertsch U, Dürig J, Ho A, Blau I, Goldschmidt H, Seckinger A, Hose D
ONCOTARGET. 2017;8(49):84847-84862.

Follow-up of patients with refractory or relapsed multiple myeloma after allogeneic hematopoietic cell transplantation
Schneidawind C, Duerr-Stoerzer S, Faul C, Kanz L, Weisel K, Bethge W, Schneidawind D
CLIN TRANSPLANT. 2017;31(7):.

A systematic literature review and network meta-analysis of treatments for patients with untreated multiple myeloma not eligible for stem cell transplantation
Weisel K, Doyen C, Dimopoulos M, Yee A, Lahuerta J, Martin A, Travers K, Druyts E, Toor K, Abildgaard N, Lu J, Van Droogenbroeck J, Geraldes C, Petrini M, Voillat L, Voog E, Facon T
LEUKEMIA LYMPHOMA. 2017;58(1):153-161.

Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma
Baertsch M, Schlenzka J, Mai E, Merz M, Hillengaß J, Raab M, Hose D, Wuchter P, Ho A, Jauch A, Hielscher T, Kunz C, Luntz S, Klein S, Schmidt-Wolf I, Goerner M, Schmidt-Hieber M, Reimer P, Graeven U, Fenk R, Salwender H, Scheid C, Nogai A, Haenel M, Lindemann H, Martin H, Noppeney R, Weisel K, Goldschmidt H
BMC CANCER. 2016;16:290.

Improved Follow-Up and Response Monitoring of Thoracic Cage Involvement in Multiple Myeloma Using a Novel CT Postprocessing Software: The Lessons We Learned
Bier G, Mustafa D, Kloth C, Weisel K, Ditt H, Nikolaou K, Horger M
AM J ROENTGENOL. 2016;206(1):57-63.

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study
Dimopoulos M, Moreau P, Palumbo A, Joshua D, Pour L, Hájek R, Facon T, Ludwig H, Oriol A, Goldschmidt H, Rosiñol L, Straub J, Suvorov A, Araujo C, Rimashevskaya E, Pika T, Gaidano G, Weisel K, Goranova-Marinova V, Schwarer A, Minuk L, Masszi T, Karamanesht I, Offidani M, Hungria V, Spencer A, Orlowski R, Gillenwater H, Mohamed N, Feng S, Chng W
LANCET ONCOL. 2016;17(1):27-38.

Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma
Dimopoulos M, Palumbo A, Corradini P, Cavo M, Delforge M, Di Raimondo F, Weisel K, Oriol A, Hansson M, Vacca A, Blanchard M, Goldschmidt H, Doyen C, Kaiser M, Petrini M, Anttila P, Cafro A, Raymakers R, San-Miguel J, de Arriba F, Knop S, Röllig C, Ocio E, Morgan G, Miller N, Simcock M, Peluso T, Herring J, Sternas L, Zaki M, Moreau P
BLOOD. 2016;128(4):497-503.

Carfilzomib alters the HLA-presented peptidome of myeloma cells and impairs presentation of peptides with aromatic C-termini
Kowalewski D, Walz S, Backert L, Schuster H, Kohlbacher O, Weisel K, Rittig S, Kanz L, Salih H, Rammensee H, Stevanović S, Stickel J
BLOOD CANCER J. 2016;6:e411.

Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial
Merz M, Salwender H, Haenel M, Mai E, Bertsch U, Kunz C, Hielscher T, Blau I, Scheid C, Hose D, Seckinger A, Jauch A, Hillengass J, Raab M, Schurich B, Munder M, Brossart P, Gerecke C, Lindemann H, Zeis M, Weisel K, Duerig J, Goldschmidt H
HAEMATOLOGICA. 2016;101(12):e485-e487.

Relationship of response and survival in patients with relapsed and refractory multiple myeloma treated with pomalidomide plus low-dose dexamethasone in the MM-003 trial randomized phase III trial (NIMBUS)
Moreau P, Weisel K, Song K, Gibson C, Saunders O, Sternas L, Hong K, Zaki M, Dimopoulos M
LEUKEMIA LYMPHOMA. 2016;57(12):2839-2847.

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
Palumbo A, Chanan-Khan A, Weisel K, Nooka A, Masszi T, Beksac M, Spicka I, Hungria V, Munder M, Mateos M, Mark T, Qi M, Schecter J, Amin H, Qin X, Deraedt W, Ahmadi T, Spencer A, Sonneveld P
NEW ENGL J MED. 2016;375(8):754-66.

Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials
Siegel D, Weisel K, Dimopoulos M, Baz R, Richardson P, Delforge M, Song K, San Miguel J, Moreau P, Goldschmidt H, Cavo M, Jagannath S, Yu X, Hong K, Sternas L, Zaki M, Palumbo A
LEUKEMIA LYMPHOMA. 2016;57(12):2833-2838.

Concomitant gain of 1q21 and MYC translocation define a poor prognostic subgroup of hyperdiploid multiple myeloma
Weinhold N, Kirn D, Seckinger A, Hielscher T, Granzow M, Bertsch U, Egerer G, Salwender H, Blau I, Weisel K, Hillengass J, Raab M, Hose D, Goldschmidt H, Jauch A
HAEMATOLOGICA. 2016;101(3):e116-9.

Spotlight on elotuzumab in the treatment of multiple myeloma: the evidence to date
Weisel K
ONCOTARGETS THER. 2016;9:6037-6048.

Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myeloma
Weisel K, Dimopoulos M, Moreau P, Lacy M, Song K, Delforge M, Karlin L, Goldschmidt H, Banos A, Oriol A, Alegre A, Chen C, Cavo M, Garderet L, Ivanova V, Martinez-Lopez J, Knop S, Yu X, Hong K, Sternas L, Jacques C, Zaki M, San Miguel J
HAEMATOLOGICA. 2016;101(7):872-8.

Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone
Dimopoulos M, Weisel K, Song K, Delforge M, Karlin L, Goldschmidt H, Moreau P, Banos A, Oriol A, Garderet L, Cavo M, Ivanova V, Alegre A, Martinez-Lopez J, Chen C, Spencer A, Knop S, Bahlis N, Renner C, Yu X, Hong K, Sternas L, Jacques C, Zaki M, San Miguel J
HAEMATOLOGICA. 2015;100(10):1327-33.

Development and Validation of A Conceptual Model of Multiple Myeloma
Gonzalez-McQuire S, Campioni M, Bennison C, Xu W, Pantiri K, Hensen M, Weisel K, Terpos E, Knop S
VALUE HEALTH. 2015;18(7):A698.

Development of A Conceptual Model of Multiple Myeloma for Use In Economic Modelling: A Systematic Literature Review to Identify The Evidence Base
Gonzalez-McQuire S, Campioni M, Bennison C, Xu W, Pantiri K, Hensen M, Weisel K, Terpos E, Knop S
VALUE HEALTH. 2015;18(7):A701.

Improvement of diagnostic confidence for detection of multiple myeloma involvement of the ribs by a new CT software generating rib unfolded images: Comparison with 5- and 1-mm axial images
Homann G, Weisel K, Mustafa D, Ditt H, Nikolaou K, Horger M
SKELETAL RADIOL. 2015;44(7):971-9.

Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma
Mai E, Bertsch U, Dürig J, Kunz C, Haenel M, Blau I, Munder M, Jauch A, Schurich B, Hielscher T, Merz M, Huegle-Doerr B, Seckinger A, Hose D, Hillengass J, Raab M, Neben K, Lindemann H, Zeis M, Gerecke C, Schmidt-Wolf I, Weisel K, Scheid C, Salwender H, Goldschmidt H
LEUKEMIA. 2015;29(8):1721-9.

Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial
Merz M, Salwender H, Haenel M, Mai E, Bertsch U, Kunz C, Hielscher T, Blau I, Scheid C, Hose D, Seckinger A, Jauch A, Hillengass J, Raab M, Schurich B, Munder M, Schmidt-Wolf I, Gerecke C, Lindemann H, Zeis M, Weisel K, Duerig J, Goldschmidt H
HAEMATOLOGICA. 2015;100(7):964-9.

Overall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the MM-003 trial for pomalidomide plus low-dose dexamethasone
Morgan G, Palumbo A, Dhanasiri S, Lee D, Weisel K, Facon T, Delforge M, Oriol A, Zaki M, Yu X, Sternas L, Jacques C, Akehurst R, Offner F, Dimopoulos M
BRIT J HAEMATOL. 2015;168(6):820-3.

Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma
San Miguel J, Weisel K, Song K, Delforge M, Karlin L, Goldschmidt H, Moreau P, Banos A, Oriol A, Garderet L, Cavo M, Ivanova V, Alegre A, Martinez-Lopez J, Chen C, Renner C, Bahlis N, Yu X, Teasdale T, Sternas L, Jacques C, Zaki M, Dimopoulos M
HAEMATOLOGICA. 2015;100(10):1334-9.

Health-related quality of life from the MM-003 trial of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed and/or refractory multiple myeloma
Song K, Dimopoulos M, Weisel K, Moreau P, Palumbo A, Belch A, Schey S, Sonneveld P, Sternas L, Yu X, Amatya R, Monzini M, Zaki M, Jacques C, San Miguel J
HAEMATOLOGICA. 2015;100(2):e63-7.

Dual-energy CT: virtual calcium subtraction for assessment of bone marrow involvement of the spine in multiple myeloma
Thomas C, Schabel C, Krauss B, Weisel K, Bongers M, Claussen C, Horger M
AM J ROENTGENOL. 2015;204(3):W324-31.

The antigenic landscape of multiple myeloma: mass spectrometry (re)defines targets for T-cell-based immunotherapy
Walz S, Stickel J, Kowalewski D, Schuster H, Weisel K, Backert L, Kahn S, Nelde A, Stroh T, Handel M, Kohlbacher O, Kanz L, Salih H, Rammensee H, Stevanović S
BLOOD. 2015;126(10):1203-13.

Successful use of eculizumab for treatment of an acute hemolytic reaction after ABO-incompatible red blood cell transfusion
Weinstock C, Möhle R, Dorn C, Weisel K, Höchsmann B, Schrezenmeier H, Kanz L
TRANSFUSION. 2015;55(3):605-10.

Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III Trial
Weisel K, Dimopoulos M, Song K, Moreau P, Palumbo A, Belch A, Schey S, Sonneveld P, Sternas L, Yu X, Amatya R, Gibson C, Zaki M, Jacques C, San Miguel J
CL LYMPH MYELOM LEUK. 2015;15(9):519-30.

Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma
Benboubker L, Dimopoulos M, Dispenzieri A, Catalano J, Belch A, Cavo M, Pinto A, Weisel K, Ludwig H, Bahlis N, Banos A, Tiab M, Delforge M, Cavenagh J, Geraldes C, Lee J, Chen C, Oriol A, de la Rubia J, Qiu L, White D, Binder D, Anderson K, Fermand J, Moreau P, Attal M, Knight R, Chen G, Van Oostendorp J, Jacques C, Ervin-Haynes A, Avet-Loiseau H, Hulin C, Facon T
NEW ENGL J MED. 2014;371(10):906-17.

Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma
Dimopoulos M, Leleu X, Palumbo A, Moreau P, Delforge M, Cavo M, Ludwig H, Morgan G, Davies F, Sonneveld P, Schey S, Zweegman S, Hansson M, Weisel K, Mateos M, Facon T, Miguel J
LEUKEMIA. 2014;28(8):1573-85.

Paraneoplastic granulocyte colony-stimulating factor secretion in soft tissue sarcoma mimicking myeloproliferative neoplasia: a case report
Dorn C, Bugl S, Malenke E, Müller M, Weisel K, Vogel U, Horger M, Kanz L, Kopp H
BMC RES NOTES. 2014;7:313.

Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial
Scheid C, Sonneveld P, Schmidt-Wolf I, van der Holt B, el Jarari L, Bertsch U, Salwender H, Zweegman S, Blau I, Vellenga E, Weisel K, Pfreundschuh M, Jie K, Neben K, van de Velde H, Duehrsen U, Schaafsma M, Lindemann W, Kersten M, Peter N, Hänel M, Croockewit S, Martin H, Wittebol S, Bos G, van Marwijk-Kooy M, Wijermans P, Goldschmidt H, Lokhorst H
HAEMATOLOGICA. 2014;99(1):148-54.

Increasing bone sclerosis during bortezomib therapy in multiple myeloma patients: results of a reduced-dose whole-body MDCT study
Schulze M, Weisel K, Grandjean C, Oehrlein K, Zago M, Spira D, Horger M
AM J ROENTGENOL. 2014;202(1):170-9.

Classical hodgkin lymphoma as de novo B-cell malignancy after treatment of multiple myeloma in the pre-lenalidomide era
Zago M, Adam P, Goldschmidt H, Fend F, Kanz L, Weisel K
CL LYMPH MYELOM LEUK. 2014;14(1):e7-e11.

Lenalidomide in relapsed and refractory multiple myeloma disease: feasibility and benefits of long-term treatment
Zago M, Oehrlein K, Rendl C, Hahn-Ast C, Kanz L, Weisel K
ANN HEMATOL. 2014;93(12):1993-9.

The BCL2 E17 and SP66 antibodies discriminate 2 immunophenotypically and genetically distinct subgroups of conventionally BCL2-"negative" grade 1/2 follicular lymphomas
Adam P, Baumann R, Schmidt J, Bettio S, Weisel K, Bonzheim I, Fend F, Quintanilla-Martínez L
HUM PATHOL. 2013;44(9):1817-26.

Cutaneous presentation of hematological malignancies
Eberle F, Metzler G, Weisel K, Berneburg M, Yazdi A
EUR J DERMATOL. 2013;23(3):372-7.

Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial
Miguel J, Weisel K, Moreau P, Lacy M, Song K, Delforge M, Karlin L, Goldschmidt H, Banos A, Oriol A, Alegre A, Chen C, Cavo M, Garderet L, Ivanova V, Martinez-Lopez J, Belch A, Palumbo A, Schey S, Sonneveld P, Yu X, Sternas L, Jacques C, Zaki M, Dimopoulos M
LANCET ONCOL. 2013;14(11):1055-1066.

Role of dynamic contrast-enhanced sonography for characterization and monitoring of extramedullary myeloma: comparison with serologic data
Pintoffl J, Weisel K, Schulze M, Maksimovic O, Claussen C, Kramer U, Horger M
J ULTRAS MED. 2013;32(10):1777-88.

Treatment with Thalidomide and Cyclophosphamide (TCID) is Superior to Vincristine (VID) and to Vinorelbine (VRID) Regimens in Patients with Refractory or Recurrent Multiple Myeloma
Auel B, Goldschmidt H, Geer T, Moehler T, Platzbecker U, Naumann R, Blau I, Hänel M, Knauf W, Nückel H, Salwender H, Scheid C, Weisel K, Gorschlüter M, Glasmacher A, Schmidt-Wolf I
INDIAN J HEMATOL BLO. 2012;28(2):67-76.

Proteasome inhibition by bortezomib: effect on HLA-antibody levels and specificity in sensitized patients awaiting renal allograft transplantation
Guthoff M, Schmid-Horch B, Weisel K, Häring H, Königsrainer A, Heyne N
TRANSPL IMMUNOL. 2012;26(4):171-5.

Extracorporeal light chain elimination: high cut-off (HCO) hemodialysis parallel to chemotherapy allows for a high proportion of renal recovery in multiple myeloma patients with dialysis-dependent acute kidney injury
Heyne N, Denecke B, Guthoff M, Oehrlein K, Kanz L, Häring H, Weisel K
ANN HEMATOL. 2012;91(5):729-735.

Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p
Neben K, Lokhorst H, Jauch A, Bertsch U, Hielscher T, van der Holt B, Salwender H, Blau I, Weisel K, Pfreundschuh M, Scheid C, Dührsen U, Lindemann W, Schmidt-Wolf I, Peter N, Teschendorf C, Martin H, Haenel M, Derigs H, Raab M, Ho A, van de Velde H, Hose D, Sonneveld P, Goldschmidt H
BLOOD. 2012;119(4):940-8.

Successful treatment of patients with multiple myeloma and impaired renal function with lenalidomide: results of 4 German centers
Oehrlein K, Langer C, Sturm I, Pönisch W, Hahn-Ast C, Kuhn S, Weisel K
CL LYMPH MYELOM LEUK. 2012;12(3):191-6.

Continuous lenalidomide treatment for newly diagnosed multiple myeloma
Palumbo A, Hajek R, Delforge M, Kropff M, Petrucci M, Catalano J, Gisslinger H, Wiktor-Jędrzejczak W, Zodelava M, Weisel K, Cascavilla N, Iosava G, Cavo M, Kloczko J, Bladé J, Beksac M, Spicka I, Plesner T, Radke J, Langer C, Ben Yehuda D, Corso A, Herbein L, Yu Z, Mei J, Jacques C, Dimopoulos M
NEW ENGL J MED. 2012;366(19):1759-69.

Osteoprotegerin positively regulates hematopoietic progenitor cells
Schweikle E, Baessler T, Yildirim S, Kanz L, Möhle R, Weisel K
CURR STEM CELL RES T. 2012;7(1):72-7.

Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial
Sonneveld P, Schmidt-Wolf I, van der Holt B, El Jarari L, Bertsch U, Salwender H, Zweegman S, Vellenga E, Broyl A, Blau I, Weisel K, Wittebol S, Bos G, Stevens-Kroef M, Scheid C, Pfreundschuh M, Hose D, Jauch A, van der Velde H, Raymakers R, Schaafsma M, Kersten M, van Marwijk-Kooy M, Duehrsen U, Lindemann W, Wijermans P, Lokhorst H, Goldschmidt H
J CLIN ONCOL. 2012;30(24):2946-55.

Can whole-body low-dose multidetector CT exclude the presence of myeloma bone disease in patients with monoclonal gammopathy of undetermined significance (MGUS)?
Spira D, Weisel K, Brodoefel H, Schulze M, Kaufmann S, Horger M
ACAD RADIOL. 2012;19(1):89-94.

Modern imaging techniques during therapy in patients with multiple myeloma
Horger M, Weisel K, Bares R, Ernemann U, Claussen C, Lichy M, Fenchel M
ACTA RADIOL. 2011;52(8):881-8.

Whole-body diffusion-weighted MRI with apparent diffusion coefficient mapping for early response monitoring in multiple myeloma: preliminary results
Horger M, Weisel K, Horger W, Mroue A, Fenchel M, Lichy M
AM J ROENTGENOL. 2011;196(6):W790-5.

Early response assessment in patients with multiple myeloma during anti-angiogenic therapy using arterial spin labelling: first clinical results
Fenchel M, Konaktchieva M, Weisel K, Kraus S, Brodoefel H, Claussen C, Horger M
EUR RADIOL. 2010;20(12):2899-906.

Response assessment in patients with multiple myeloma during antiangiogenic therapy using arterial spin labeling and diffusion-weighted imaging: a feasibility study
Fenchel M, Konaktchieva M, Weisel K, Kraus S, Claussen C, Horger M
ACAD RADIOL. 2010;17(11):1326-33.

Imaging findings in relapsing multiple myeloma
Sauter A, Weisel K, Horger M
BRIT J HAEMATOL. 2010;150(4):388.

A phase II study of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomas
Weidmann E, Hess G, Chow K, Krause S, Subklewe M, Kruse J, Weisel K, Soekler M, Kim S, Napieralski S, Rech J, Dreyling M, Jäger E, Mitrou P
LEUKEMIA LYMPHOMA. 2010;51(3):447-55.

Wnt1 overexpression leads to enforced cardiomyogenesis and inhibition of hematopoiesis in murine embryonic stem cells
Weisel K, Kopp H, Moore M, Studer L, Barberi T
STEM CELLS DEV. 2010;19(5):745-51.

Severe psychotic disorder and agranulocytosis--a therapeutic dilemma
Borbé R, Weisel K, Sachs U, Steinert T
PHARMACOPSYCHIATRY. 2009;42(6):284-5.

Rhabdomyolysis and acute kidney injury
Heyne N, Guthoff M, Weisel K
NEW ENGL J MED. 2009;361(14):1412; author reply 1412-3.

Contamination of autologous peripheral blood progenitor cell grafts predicts overall survival after high-dose chemotherapy in multiple myeloma
Kopp H, Yildirim S, Weisel K, Kanz L, Vogel W
J CANCER RES CLIN. 2009;135(4):637-42.

DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed myeloma
Kropff M, Liebisch P, Knop S, Weisel K, Wand H, Gann C, Berdel W, Einsele H
ANN HEMATOL. 2009;88(11):1125-30.

Pathologic fractures in patients with multiple myeloma undergoing bisphosphonate therapy: incidence and correlation with course of disease
Vogel M, Weisel K, Maksimovic O, Peters S, Brodoefel H, Claussen C, Horger M
AM J ROENTGENOL. 2009;193(3):656-61.

Modulation of CXC chemokine receptor expression and function in human neutrophils during aging in vitro suggests a role in their clearance from circulation
Weisel K, Bautz F, Seitz G, Yildirim S, Kanz L, Möhle R
MEDIAT INFLAMM. 2009;2009:790174.

Development of rapid light-chain deposition disease in hepatic arteries with severe ischemic cholangitis in a multiple myeloma patient treated with melphalan, prednisone and lenalidomide
Weisel K, Böckeler M, Bianchi L, Terracciano L, Mayer F, Kanz L
INT J HEMATOL. 2009;89(1):91-94.

International Symposium and Workshop on hematopoietic stem cells VII, University of Tübingen, Germany, September 18-20, 2008
Weisel K, Dick J, Fibbe W, Kanz L
ANN NY ACAD SCI. 2009;1176:1-17.

Extended in vitro expansion of adult, mobilized CD34+ cells without significant cell senescence using a stromal cell coculture system with single cytokine support
Weisel K, Moore M, Kanz L, Möhle R
STEM CELLS DEV. 2009;18(2):229-34.

Regulation of FLT3 and its ligand in normal hematopoietic progenitor cells
Weisel K, Yildirim S, Schweikle E, Kanz L, Möhle R
ANN HEMATOL. 2009;88(3):203-11.

European trial of free light chain removal by extended haemodialysis in cast nephropathy (EuLITE): a randomised control trial
Hutchison C, Cook M, Heyne N, Weisel K, Billingham L, Bradwell A, Cockwell P
TRIALS. 2008;9:55.

OP9 stroma augments survival of hematopoietic precursors and progenitors during hematopoietic differentiation from human embryonic stem cells
Ji J, Vijayaragavan K, Bosse M, Menendez P, Weisel K, Bhatia M
STEM CELLS. 2008;26(10):2485-95.

Epstein-Barr virus-associated B-cell lymphoma secondary to FCD-C therapy in patients with peripheral T-cell lymphoma
Weisel K, Weidmann E, Anagnostopoulos I, Kanz L, Pezzutto A, Subklewe M
INT J HEMATOL. 2008;88(4):434-440.

Meeting summary: International Symposium and Workshop on Hematopoietic Stem Cells VI, University of Tübingen, Germany, September 14-16, 2006
Weisel K, Fibbe W, Kanz L
EXP HEMATOL. 2007;35(7):1005-14.

Effect of FLT3 inhibition on normal hematopoietic progenitor cells
Weisel K, Yildirim S, Schweikle E, Kanz L, Möhle R
ANN NY ACAD SCI. 2007;1106:190-6.

Differential effects of G protein coupled receptors on hematopoietic progenitor cell growth depend on their signaling capacities
Xue X, Cai Z, Seitz G, Kanz L, Weisel K, Möhle R
ANN NY ACAD SCI. 2007;1106:180-9.

Progressive bicytopenia due to persistent parvovirus B19 infection after immunochemotherapy with fludarabine/cyclophosphamide and rituximab for relapsed B cell lymphoma
Hartmann J, Meisinger I, Kröber S, Weisel K, Klingel K, Kanz L
HAEMATOLOGICA. 2006;91(12 Suppl):ECR49.

Stromal cell lines from the aorta-gonado-mesonephros region are potent supporters of murine and human hematopoiesis
Weisel K, Gao Y, Shieh J, Moore M
EXP HEMATOL. 2006;34(11):1505-16.

Meeting summary: International Symposium and Workshop on Hematopoietic Stem Cells V, University of Tübingen, Germany, September 16-18, 2004
Weisel K, Brümmendorf T, Orlic D, Fibbe W, Kanz L
EXP HEMATOL. 2005;33(5):513-22.

Genetic and functional characterization of isolated stromal cell lines from the aorta-gonado-mesonephros region
Weisel K, Moore M
ANN NY ACAD SCI. 2005;1044:51-9.

Elevated telomerase activity and minimal telomere loss in cord blood long-term cultures with extensive stem cell replication
Gammaitoni L, Weisel K, Gunetti M, Wu K, Bruno S, Pinelli S, Bonati A, Aglietta M, Moore M, Piacibello W
BLOOD. 2004;103(12):4440-8.

Intravascular lymphoma - a rare cause of hemolytic anemia and neurologic disorders
Weisel K, Brugger W, Kröber S, Kaiserling E, Kanz L
HEMATOL J. 2004;5(5):444-6.

Letzte Aktualisierung aus dem FIS: 21.11.2024 - 03:37 Uhr